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Ricin toxin’s enzymatic A subunit (RTA) is a 267 amino acid RNA N-glycosidase that depurinates     
a conserved adenine residue of 28S rRNA, resulting in ribosome arrest and apoptosis. One of the 
leading subunit vaccine candidates for ricin is RiVax, a two point mutant (V76M, Y80A) of RTA. 
RiVax has proven to be safe in humans, however, it could not elicit a robust toxin-neutralizing 
antibody response. In order to redesign a potent ricin subunit vaccine candidate based on RTA, an 
immunological rationale has to be implemented. Protection against ricin is antibody mediated and 
hence generating a comprehensive B cell epitope map of ricin toxin would not only help in 
evaluating future ricin vaccine candidates in humans but also provides an immunological rationale 
for designing new vaccine candidates. Previous studies have shown that toxin neutralizing 
antibodies recognized four immunodominant regions on RTA i.e. four epitope clusters (namely 
cluster I to IV). RTA’s active site is surrounded by cluster III. Surprisingly, mAb IB2, which 
defines cluster III is the only antibody that recognized this immunodominant region. We 
previously showed that IB2 binds to helices C and G on the surface of RiVax. In this study, we 
sought to gain a better understanding of cluster III using a collection (21) of single domain 
antibodies (VHHs) that are derived from ricin immunized alpacas. To this end, I first produced and 
characterized RiVax (a safer version which is structurally identical to RTA) for its structural 
integrity since our main emphasis lies in identifying discontinuous/ conformational epitopes. 
Based on hydrogen exchange mass spectrometry (HX-MS) studies, VHHS recognized overlapping 
epitopes with four spatially distinct contact regions i.e. they were grouped into four subclusters 
(namely 3.1 to 3.4) within cluster III region.  Subcluster 3.1 includes helices C and G. Subcluster 




helices B and G, subcluster 3.4 includes helices C, E and strand h. Of the 21 antibodies that we 
analyzed, only two, namely V1D3 and V6D4 have shown toxin neutralizing activity (TNA).  Both 
neutralizing antibodies have strong binding affinity (sub nanomolar range) to the toxin and 
engaged a common secondary structural element, namely helix G as part of their epitope. 
The second part of my dissertation focusses on fibroblast growth factor-1 (FGF-1), a member of 
β-trefoil family of proteins. FGFs regulate a number of developmental process including 
mitogenesis, angiogenesis and homeostasis etc. Due to their wide range of biological activities, 
FGFs has been of interest in several clinical applications. In particular, wound healing has 
generated considerable interest. Studies have shown that several polyanions (sulfated and 
phosphorylated) have increased the thermal stability of FGF-1 by 15-30oC.  In this study, we 
sought to identify the binding sites of the polyanions. In particular, we studied two sulfated 
(heparin, low MW heparin) and two phosphorylated (phytic acid and ATP) polyanions. Using HX-
MS, we examined the local dynamics as well as binding sites of the polyanions. For local 
dynamics, we identified strand 4 and 5 and the turn connecting them to be most flexible which 
agrees with previous NMR studies. On the other hand, strands 8, 9 and 10 appear to be more rigid 
which is consistent with crystallographic B factors as well as local dynamic studies conducted by 
NMR. Crystal studies have shown that heparin binds to N-terminal Asn18 and to C-terminal 
Lys105, Tryp107, Lys112, Lys113, Arg119, Pro121, Arg122, Gln127 and Lys128 indicating 
electrostatic forces as the dominant interactions. Heparin binding as determined by HX-MS is 
consistent with the crystallography data. We find other polyanions tested bind in a similar manner 
to heparin, primarily targeting the turns in the lysine rich C-terminal region of FGF-1 along with 
two distinct N-terminal regions that contains lysines and arginines/ histidines. This confirms the 
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 Ricin: Recent incidents in the United States and abroad have increased concerns about the use of 
ricin toxin as a bioterrorism agent. Ricin is a member of the type II ribosome-inactivating protein 
(RIP) family of toxins found in plant and microbes. Ricin is found in the seeds of the castor oil 
plant, Ricinus communis which is ubiquitous in tropical environments. In its mature form, ricin is 
a 64 kDa glycoprotein composed of a 32 kDa enzymatic ricin A (RTA) subunit which is joined by 
a disulfide bond to a 32 kDa ricin B (RTB) subunit (1-4). RTA, which is 267 amino acids in length 
is an RNA N-glycosidase that inactivates eukaryotic ribosomes by selectively cleaving the 
conserved adenine residue (A2662) within the sarcin-ricin loop (5-7).  RTA’s catalytic activity is 
essentially performed by five residues: Tyr80, Tyr123, Arg180, Glu177 and Trp211 (8, 9). Ricin 
is internalized into cells through its binding subunit RTB which binds to α (1-3)-linked galactose 
and N-actetylgalactosamine residues on the surface of almost all cell types (10-12). Once attached, 
ricin is internalized into endosomes by mechanisms that are clatherin-dependent and independent 
and then into the trans-Golgi network (TGN) by a process known as retrograde transport and 
eventually into the endoplasmic reticulum. In the endoplasmic reticulum, the two subunits of ricin, 
RTA and RTB, that are joined by disulfide bond separate in the presence of protein disulfide 
isomerase and endoplasmic reticulum degradation- enhancing α-mannosidase I-like protein 1(13-
15). RTA is then transported across the endoplasmic reticulum membrane and into the cytoplasm, 
a process known as retro-translocation, where RTA refolding is facilitated by cytoplasmic 
chaperons and possibly by ribosomes as well (16-19). The refolded RTA in the cytoplasm then 
cleaves the N- glycosidic bond of a conserved adenosine residue within the sarcin-ricin loop of 
28S RNA leading to an immediate arrest in ribosome progression and inhibition in translation (6, 
20). Damaging ribosomal RNA activates the ribotoxic stress response involving stress-activated 
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protein kinases, leading to production of pro-inflammatory cytokines and eventually apoptosis 
mediated cell death (21, 22). 
Structure of ricin: Ricin holotoxin is composed of two subunits RTA and RTB joined by a disulfide 
bond. RTA is 267 amino acids in length and is structurally divided into three distinct folding 
domains (2, 3). Folding domain I (1-117) is dominated by a six stranded β-sheet that terminates in 
a solvent exposed loop-helix-loop (23). The solvent exposed α-helix, known as helix B is 
conserved among all other structurally similar ribosome inactivating proteins and is a target of 
three toxin neutralizing murine monoclonal antibodies including PB10, R70 and 6C2 (23-27). 
Previous studies suggested that the loop-helix-loop motif may influence the orientation of the 
glutamic acid 177 (E177) side chain, which is critical for RTA’s catalytic activity i.e. depurination 
(24).  Folding domain II (118-210) is dominated by five α-helices (C-G). Helix E which runs 
through the center of RTA terminates with two residues (E177 and R180) that are involved in its 
catalytic activity. An arginine rich sequence spanning from residues 187-198 (EMRTRIRYNRRS) 
forms a positively charged patch and is speculated to be responsible for RTA’s initial contact with 
rRNA (3). Folding domain III (211-267) forms a protruding element that slides into the cleft 
between RTB’s two domains (2). The nature of interaction between folding domain III of RTA 
and RTB is hydrophobic and is further fortified by a disulfide bond between Cysteine 259 of RTA 
and Cysteine 20 of RTB. The C-terminus of RTA which is relatively disordered (intrinsically 
thermally unstable) compared to folding domain I and II may drive the unfolding of RTA and 
thereby facilitate translocation from the endoplasmic reticulum into the cytosol. RTA’s enzymatic 
activity involves five residues that include Tyr80, Tyr123, Glu177, Arg180 and Trp211 that are 
situated within or near the active site (3, 9). 
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Ricin’s binding subunit, RTB, is 262 amino acids in length that consists of two globular domains 
which are involved in RTB’s ability to attach to the cell surfaces (2, 12). The two domains which 
have similar folding topologies are further divided into three homologous sub-domains (α, β, γ). 
Subdomains 1α and 2γ have functional carbohydrate recognition activity. While the subdomain 1α 
binds Gal with low affinity, subdomain 2γ binds both Gal and GalNAc and is considered a high 
affinity carbohydrate recognition domain (28-30). 
Ricin vaccine development: Over the past several decades, a number of candidate ricin vaccines 
have been explored. Ricin toxoid is capable of stimulating systemic and mucosal immunity in 
rodent models (31-33). Deglycosylated RTA has been tested as well in rodents (34). However, due 
to the residual toxicity associated with ricin toxoid as well as the deglycosylated RTA not eliciting 
RTA specific titers that are significant enough to protect made the development of both types of 
vaccines to be abandoned. The ongoing efforts are focused on the development of recombinant, 
attenuated and stable derivatives of RTA (35, 36). The two most promising subunit vaccines are 
devoid of enzymatic activity, yet retain the tertiary structure of ricin and are designated RiVax and 
RVEc. Both are non-toxic derivatives of ricin’s enzymatic subunit, RTA. RiVax, a full length 
variant (267 amino acids) of RTA was developed by Dr. Ellen Vitetta at the University of Texas 
Southwestern (37). Two site specific mutations were engineered in RiVax at positions 76 (V76A) 
and 80 (Y80A). The mutation at the key active site residue at position 80 (Y80A) eliminates the 
enzymatic activity (> 1000 fold). The second mutation at position 76 eliminates RTA’s induced 
vascular leak syndrome (37, 38). The resulting recombinant protein, RiVax is virtually identical 
to RTA i.e. the two mutations have minimal effect on the tertiary structure of the protein (39).  
                       The second RTA derivative being pursued as a vaccine is RVEc, developed by 
investigators at the U.S. Army, is a truncated version of RTA that lacks the C-terminal residues, 
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199-267 as well as a small hydrophobic loop (residues 34-43) in the N-terminus (40-42). These 
deletions/ truncations are engineered to reduce the RTA’s intrinsic propensity to aggregate and 
precipitate from solution, i.e. to enhance the stability. The crystal structure of RVEc (PDB: 3LC9) 
reveals the atomic structure is essentially superimposable onto RTA (43). Despite lacking folding 
domain 3, RVEc still assumes RTA’s normal tertiary structure across folding domains 1 and 2 
which is certainly integral to the success of the vaccine. A number of potent toxin- neutralizing 
antibodies are known to bind in a conformationally dependent manner within folding domains 1 
and 2 (25). 
 
Figure 1: Ribbon diagram of RiVax (PDB: 3SRP): Gray represents the deleted regions in RVEc. 
       Both RiVax and RVEc have been subjected to extensive preclinical testing in mice and rabbits. 
RiVax, when administered to mice by the subcutaneous, intradermal and intramuscular routes has 
shown to elicit protective immunity against systemic and mucosal challenges (36, 37, 44-46). 
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RVEc, when given parenterally, protected mice and rabbits from both systemic and mucosal ricin 
challenge (40, 41, 47, 48). Recently, the two vaccines (RiVax and RVEc) have been compared 
side by side in mice (49). Both RiVax and RVEc are found to be identical although RVEc was 
slightly more effective than RiVax at eliciting toxin specific IgG titers and toxin neutralizing 
activity (TNA) when administered subcutaneously to mice.    
Phase I clinical trials with RiVax and RVEc: Two pilot I clinical trials were recently completed in 
which RiVax and RVEc, each adsorbed to Alhydrogel, were administered to healthy individuals. 
Both vaccines performed similarly to each other (50, 51). Immunogenicity was based on ricin 
specific serum IgG levels as determined by ELISA, while toxin-neutralizing activity (TNA) was 
measured using mammalian cell based cytotoxicity assays. Direct comparisons between RiVax 
and RVEc were slightly complicated in that different methods were used to assess the endpoint 
titers and TNA in each case. Despite these differences there are obvious comparisons that can be 
made. In terms of safety, both RiVax and RVEc are similar to each other in that the vast majority 
(80-100%) of human volunteers reported a mild (grade I) systemic adverse events following 
vaccination. TNA is the indicator that is most closely associated with immunity to ricin and 
therefore a critical measure of vaccine efficacy. Unfortunately, neither RiVax nor RVEc were 
effective at eliciting TNA in human participants. In the case of RVEc, only 40-50% of the 
vaccinated individuals showed detectable TNA in their sera after a third vaccination. This is 
slightly better than the case of RiVax in that all of the vaccinated individuals produced detectable 
TNA, although their actual titers were very low. In summary, both vaccines were deemed to be 
comparatively safe and immunogenic in humans. But, neither RiVax nor RVEc proved particularly 
effective at eliciting toxin-neutralizing activity. While this issue could potentially be addressed 
with more potent adjuvant(s), the ultimate success of the ricin vaccine program requires more 
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established surrogate/correlate markers of protection that can be used to assess the efficacy of the 
vaccine on humans as reported in (52). 
RiVax-induced immunity to ricin toxin challenge in non-human primates: Recent RiVax 
vaccination/aerosol challenge studies in rhesus macaques have provided a key step in the 
development of a ricin toxin subunit vaccine (53). Following aerosolized toxin challenge, the 
RiVax- vaccinated animals all survived while the control animals expired. This is the first study 
demonstrating that parenteral vaccination of non-human primates with a recombinant RTA-based 
subunit vaccine is sufficient to confer protective immunity to an aerosolized challenge. This type 
of study (vaccination/aerosolized challenge) were conducted previously in only mice, rats and 
rabbits (44, 45, 48). The demonstration of rhesus macaques being rendered immune to inhaled 
ricin toxin supports the continued development of RiVax (and/ or RVEc) for use in humans. 
Comparisons were made regarding the relative magnitudes of toxin specific responses between 
rhesus macaques and human studies that received RiVax. It should be noted that the RiVax vaccine 
antigen used in both the studies differ in that the human studies used a freshly prepared RiVax 
adsorbed to Alhydrogel while in the case of non-human primates (Rhesus macaques) a lyophilized 
formulation of RiVax adsorbed to Alhydrogel was used. It was seen that following RiVax 
vaccination in Rhesus macaques, they had peak toxic- specific serum IgG levels that were 10 times 
greater than those observed in human volunteers. At the time of challenge, however, toxin specific 
serum IgG levels declined to just 2-3 times over the levels achieved in humans that received three 
vaccinations with RiVax. In monkeys, TNA was reported as endpoint titers, while in human 
samples they were reported as µg/ mL and hence it is not possible to directly compare the two 
species in terms of toxin-neutralizing antibodies. This implies that there is a need to establish 
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standardized and universally accepted assays so that critical parameters like toxin neutralization 
can be compared across different clinical trials and species.     
Challenges in ricin toxin vaccine development: Despite its initial success, RiVax and /or RVEc 
developmental progress has been hindered by additional challenges including stability, 
adjuvanticity and assessing RiVax and RVEc’s efficacy in humans in the absence of challenge 
studies in humans, especially considering the fact that the exact correlates of immunity to ricin are 
poorly understood.  
RiVax is relatively unstable in solution and has a tendency to unfold and aggregate. This would 
limit the shelf life of a candidate ricin vaccine (40, 41). RiVax’s stability issue has been addressed 
by both liquid formulation and lyophilization technology where RiVax adsorbed to alum in 
histidine and ammonium acetate buffers were lyophilized with trehalose as a stabilizing excipient 
(54). In the case of RVEc, the issue of stability is addressed by deleting the relatively disordered 
C-terminal region and loops involved in unfolding (41) as well as by a rational engineering of  
disulfide bonds (55).  
Phase I clinical trials have shown that both RiVax and RVEc that are adsorbed to aluminum 
hydroxide didn’t produce robust responses in humans. The serum IgG titers were slow to peak and 
even after a prime and two boosts, toxin neutralizing antibodies are barely detectable or just above 
the baseline (50, 51). Hence, there is a need to develop different next generation adjuvants and 
investigate their effects on RiVax and RVEc. 
One of the main obstacles to developing a ricin toxin subunit vaccine is evaluating or assessing 
RiVax’s or RVEc’s efficacy in humans in the absence of human challenge studies (which are 
obviously unethical) especially when the exact correlates of immunity to ricin are poorly 
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understood. Studies in mice have shown that toxin neutralizing antibodies are important in 
protection against systemic and mucosal ricin exposure. There has been many reports in the 
literature towards this end demonstrating that passive administration of a toxin neutralizing 
monoclonal antibody (mAb), Fab fragments or polyclonal antibody (pAb) mixture is sufficient to 
render mice impervious to a lethal dose of ricin administered by inhalation, ingestion or injection 
(56-61). While on the other hand, studies have also shown that toxin–specific serum IgG levels, at 
least in mice, are not good indicators of immunity. It was reported that mice with similar endpoint 
titers experience different fates upon ricin challenge: some survive while others succumb to death 
only marginally better than unvaccinated control animals implying that the quality rather than 
quantity of the antibodies is the important factor in determining protection. At present, In vitro 
neutralizing activity using mammalian cell-based cytotoxicity assays has been the sole measure of 
the “quality” of an anti-ricin antibody response. Over the past few years of RiVax and RVEc 
studies in mice, it was found that animals with detectable serum toxin neutralizing activity have 
survived a lethal dose ricin challenge (49, 62, 63). Hence, toxin neutralizing activity can be 
considered an absolute correlate of protection. However, TNA itself may be too strict a threshold 
by which to judge protection since it has been reported in mice that even in the absence of 
detectable TNA, survival was achieved following a lethal dose ricin challenge (49, 62, 63).  One 
of the studies conducted by O’Hara and colleagues have shown all mice that are vaccinated (RiVax 
and RVEc adsorbed on alhydrogel) survive 10xLD50 ricin toxin challenge even though none of 
them had any detectable TNA in their sera. It was speculated that the circulating toxin-neutralizing 
antibody levels are below the limit of detection of the cell- based assays that are used (26). Another 
possibility is that a polyclonal mixture of non–neutralizing antibodies (as determined using in vitro 
assays) may have the ability to inactivate ricin in vivo through some mechanism that have not been 
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identified yet. Indeed, little is known about the exact mechanisms by which ricin is neutralized in 
vivo. 
Epitope specific serum antibody profiling in assessing vaccine efficacy 
Immune signature analysis or serum antibody profiling is an emerging application in vaccinology 
and could be well suited for use by the ricin toxin vaccine community (64, 65). Our collaborators 
have shown that in the case of ricin, toxin-neutralizing antibodies constitute only a minor portion 
(10%) of the antibody response elicited by RiVax and RVEc. It was also reported that neutralizing 
antibodies recognize a very limited number of critical/hot spots on the surface of RTA (25, 26). 
These hot spots are referred to as epitope clusters I-IV.  
An epitope is the part of the antigen/toxin to which an antibody binds. An antibody can recognize 
either linear or conformational epitopes on the surface of an antigen/toxin. Linear epitopes consist 
of small stretches of contiguous amino acids within the primary structure of a protein antigen. 
Linear epitopes can be identified using peptide based approaches like peptide array analysis. On 
the other hand, conformational epitopes consist of amino acids that are apart from one another in 
the primary structure although, they are brought near one another in folded state of the protein 
antigen. Conformational epitopes can be identified by X-ray crystallography, nuclear magnetic 
resonance (NMR) or hydrogen deuterium exchange mass spectrometry (HX-MS).  
Two potent ricin-neutralizing murine mAbs, UNIVAX 70 and PB10, target the cluster I region on 
RTA. UNIVAX 70 was identified by Lemley and colleagues (66), while, PB10 was reported by 
O’Hara and colleagues (26). Using peptide array analysis, both mAbs have been shown to 
recognize a “linear epitope” in helix B (residues 97-107) of RTA. Recently, Zhu and colleagues 
have solved the crystal structure of a toxin-antibody complex which enabled atomic level 
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resolution of epitopes in cluster I (67). The Fab Fragment of 6C2 (a PB10-like mAb) was co-
crystallized with RTA which revealed antibody primarily in contact with helix B (residues 97-
107).  The other three epitope clusters (II-IV) were defined by mAbs SyH7, IB2 and GD12 (25, 
26). Cluster II is defined by SyH7 which recognizes a conformational epitope in helix F (residues 
187-198). IB2, defines cluster III and recognizes helix C (residues 123-130) and cluster IV by 
GD12 which recognizes a linear epitope in helix E (residues 163-174).  
To assess the utility of immune profiling analysis for a ricin vaccine, sera from Phase I clinical 
trial volunteers and RiVax vaccinated macaques were subjected to direct competition ELISA with 
toxin neutralizing murine mAbs directed against cluster I (PB10, UNIVAX 70) and cluster II 
(SyH7). It was reasoned by our collaborators that the degree to which an antiserum reduced binding 
of cluster I and II specific mAbs would serve as indirect indicator of epitope utilization. Towards 
this end, they observed the antisera from both RiVax vaccinated humans and macaques reduced 
binding of cluster I and II specific mAbs ranging from 10-80% depending on the specific mAb. It 
was found both monkeys and humans have similar inhibitory profiles which suggests that the 
antibody response is conserved between the species. This data suggests the possibility that serum 
antibody profiling can be useful in assessing vaccine efficacy. The inter relationship, however, 
between mAb competition, toxin-neutralizing activity and protection has yet to be made.  
Comprehensive B-cell epitope mapping: It was initially reported that RTA has four immune 
dominant regions which are referred to as epitope clusters I-IV. However, these conclusions are 
based on mAbs that recognize linear epitopes. O’Hara et al. reported that most of the toxin 
neutralizing mAbs bind RTA in a conformationally dependent manner i.e. they recognize 
conformational epitopes. Recently, we have reported epitopes of nine toxin- neutralizing mAbs 
and one non-neutralizing mAb on RTA* (two point mutated version of RTA) using HX-MS (68). 
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These antibodies were categorized into clusters I-IV based on contacts with RTA secondary 
structural elements. All antibodies except GD12 have recognized primarily the same secondary 
structural elements as is seen in peptide array analysis. Epitope analysis of GD12 using hydrogen 
deuterium exchange mass spectrometry contradicts GD12 epitope determined by peptide array 
analysis in which it recognized strands b and c and the two interconnecting β-turns. By all accounts, 
Clusters I–IV represent the most immunodominant regions on the surface of RTA. To investigate 
these clusters in more detail, our collaborators have screened a large library of single domain 
camelid antibodies (VHHs) from RiVax and ricin toxoid vaccinated alpacas (69). 
VHH: In certain mammals belonging to the camelidae family (camels, Ilamas, and alpacas) as well 
as cartilaginous fishes, along with conventional antibodies in their sera, they possess about 45-
75% of heavy chain only antibodies (70). Heavy chain antibodies are homodimers of disulfide 
linked heavy chains and are completely devoid of light chains. These antibodies are fully capable 
of antigen binding i.e. the antigen binding site of heavy chain antibodies is formed by only three 
complementary determining regions (CDRs) compared to the usual six CDRs which include three 
each from heavy and light chain in conventional antibodies. Of the three CDRs in the heavy chain 
antibodies, CDR3 which usually plays the dominate role in antigen binding is a long finger- like 
poly peptide loop. Hence, the antigen binding site of heavy chain antibodies forms a convex 
protruding shape and differs from that of the antigen binding site of conventional antibodies which 
form a concave shape (groove like). This convex shaped antigen binding site creates heavy chain 
antibodies which recognize cryptic (buried in the cleft) epitopes on protein surfaces as reported in 
(71). The fact that just an N–terminal single domain (variable domain, VH) that contains the three 
CDRs retains their functional activity makes them attractive for use as a second generation of 
therapeutic agents and immunoreagents. This single domain antibody which represents just a 
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variable domain is termed a VHH rather than VH as in conventional antibodies. The insertion of 
another H in VHH is to just distinguish them as having originated from a heavy chain antibody 
rather than from a conventional antibody. VHHs, which are of 15 kDa and non-glycosylated are 
reported to be well expressed in E. coli (72). The unique characteristics of VHHs such as low 
molecular weight, good water solubility (73), high physical-chemical stability (74), ability to fold 
after heating to attain their original native structure (75, 76) and the ability to bind buried epitopes 
on an antigen that are inaccessible to conventional antibodies (71) can potentially make them a 
substitute for conventional therapeutic drugs in the treatment of serious human diseases. They 
could also be broadly used in diagnostics.  
Earlier, cluster I was interrogated in more detail using alpaca derived VHHs based on competition 
ELISAs with PB10 (the cluster I defining mAb) as well as solving VHH-RTA crystal structures 
(69, 77, 78).  To date, seven crystal structures of cluster I VHHs in complex with RTA were solved 
(78, 79). These seven VHHs differ in the degree to which they make contact with helices B 
(residues 97-107), D (residues 150-157) and strand h (residues 113-117). Previously, cluster II was 
studied using four murine mAbs that includes SyH7, PA1, TB12 and PH12 where it was identified 
that cluster II possess two subclusters based on the binding sites of the four mAbs (68). Alpaca 
derived VHHs were also used to study cluster II (77). Recently, we tried to further our 
understanding of cluster II by studying additional cluster II specific murine mAbs (Greta van slyke 
et.al. 2018, manuscript submitted). 
           The first part of my dissertation focuses on interrogating cluster III with RTA specific 
VHHs. It should be noted that due to safety issues, we worked on RTA
* rather than the toxic version 
of RTA. RTA* is a two point mutated (V76M, Y80A) version of RTA that eliminates the enzymatic 
activity. Both, RTA and RTA* are essentially structurally identical and hence the safer version, 
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RTA*, was used to map structural epitopes. More emphasis is placed on conformational epitopes 
since most of the ricin specific antibodies bind to RTA in a conformationally dependent manner 
i.e. they have conformational epitopes. A variety of methods are commonly used to map the fine 
details of interaction between antigen and an antibody. X-ray crystallography is by far the best in 
that it provides detail at the level of individual amino acids and atoms. The feasibility of 
performing crystal studies has increased over the years with automation, miniaturization and high 
through put processes. Our collaborators were successful in solving the co-crystals of RTA with 
VHHs (78, 79). However, it still requires a high level of sophistication and is particularly 
challenging to crystallize an antigen with its cognate monoclonal antibody. Nuclear magnetic 
resonance spectroscopy (NMR) also offers individual amino acid level resolution similar to 
crystallography but the technical hurdles are even higher when the size of the protein of interest 
increases above a certain limit (typically 30kDa) (80). Peptide based approaches coupled with 
ELISA-based approaches can be used to map information over a peptide region i.e. linear epitopes 
can be identified. However, this method is of limited use in identifying conformational epitopes. 
Hydrogen-deuterium exchange coupled with mass spectrometry can be used to identify both linear 
and conformational epitopes albeit at a peptide level resolution. In this dissertation, we have 
chosen HX-MS as a method of choice to identify epitopes on RTA* based on its recent success in 








Hydrogen/ deuterium exchange (HX) was first described by Hvidt and Linderstorm-Lang in 1954 
(85). Initially, HX has been detected using various spectroscopic techniques including FTIR, NMR 
as well as size exclusion chromatography using tritium to study protein structure and dynamics 
(86, 87). The coupling of mass spectrometry (MS) to study HX was first described in 1991 (88). 
Further improvements in HX-MS was accomplished by pairing the experiment with proteolytic 
digestion (89). This enabled the study of structural changes to be resolved at the peptide level 
(typically 5-10 amino acids). HX is sensitive to changes in protein conformation and has gained 
popularity within the bio-pharmaceutical industry (90-92). 
When a protein is in solution, certain hydrogens are in continuous exchange with the hydrogens in 
solution. If an aqueous solvent is replaced with deuterated or (heavy) water (D2O), then one can 
follow this exchange process. The exchange of hydrogen (more accurately protium, 1H) with 
deuterium (2H) induces an increase in 1 Da which permits one to track HX events using MS. In 
proteins, three types of hydrogens are present. i) hydrogens that are bonded to carbon. ii) hydrogens 
that are bonded to side chain atoms iii) and hydrogens that are bonded to backbone amide nitrogen. 
Hydrogens bonded to carbon barely exchange. While, the hydrogens that are bonded to side chain 
sites (O-H, N-H, and S-H) undergo exchange, however, the rate of exchange is very fast such that 
any deuterium incorporated will undergo rapid back exchange during LC processes. Most 
importantly, the hydrogens that are bound to the backbone amide nitrogens exchange at 
intermediate rates. Using HX-MS methods one can follow back bone amide hydrogen exchange 
processes i.e. the backbone dynamics of the protein can be followed. Except proline, every amino 
acid has a backbone amide hydrogen i.e. there is a sensor at every amino acid along the length of 
the protein chain. There are various factors that influence the HX process in proteins, of which the 
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primary factors are temperature, pH, hydrogen bonding and solvent accessibility. Of the above 
four factors, temperature and pH can be controlled experimentally leaving the structurally related 
parameters of hydrogen bonding and solvent accessibility as the governing factors in deuteration. 
In other words, the rate and location of exchange becomes a function of hydrogen bonding and 
solvent accessibility. Regions that are highly dynamic and solvent exposed (like the loops that 
connect α-helices) exchange fast. In contrast, the regions that are rigid (less dynamic) and involved 
in hydrogen bonding networks or buried within the interior of a protein such as β-sheets and α-
helices exchange slowly. In folded proteins, the exchange of these backbone amide hydrogens vary 
from seconds to days depending on their location (93, 94).   
The mechanism of backbone amide HX for native proteins under continuous labelling conditions 
can be expressed in equation 1:  
 
 N-Hclosed           N-Hopen               N-Dopen              N-Dclosed                               (1) 
 
Where, kcl and kop are rate constants for opening and closing events, respectively, while kch is the 
chemical rate constant for an amide hydrogen to deuterium (N-H to N-D) conversion.  Every N-H 
group may exhibit a unique combination of kcl, kop and kch. 
The equation suggests that the exchangeable backbone sites fluctuate between closed (exchange 
incompetent) and open (exchange competent) sites.  Breathing motion in proteins can transiently 
break amide hydrogen bonds in the folded state (N-H closed) which allows access to the OD-
(catalyst under physiological condition). Equation 1 is typically considered for two limiting 







kcl, implying that the backbone amide hydrogen labelling occurs once the protein unfolds (during 
the very first opening event) such that  
                                                      kHX= kop                                                   (2) 
EX1 kinetics are seen as evidence that HX proceeds via global or subglobal unfolding of a protein. 
Therefore many proteins can be induced to undergo HX by the EX1 mechanism by subjecting the 
proteins to denaturants (95). While it has been noted that only a few proteins exchange by the EX1 
mechanism under native conditions (96) it is the EX2 mechanism that predominates in most folded 
proteins. EX2 is characterized by kcl>> kch leading equation 1 to the expression  
                                                    kHX= Kopkch                                              (3) 
Where, Kop= (kop/kcl) is the equilibrium constant of the opening reaction. Under EX2 conditions 
the possibility of HX occurring during a single opening event is small and numerous 
opening/closing transitions may occur before an isotope exchange event occurs in a given amide.  
 Most HX-MS studies use a continuous labelling strategy where the native protein is placed in D2O 
solvent for a certain period of time (usually minutes to hours) such that the deuterium incorporation 
can be monitored as a function of exposure time. According to equation 1, continuous labelling 
HX primarily monitors protein structural dynamics rather than structure per se. Nevertheless, there 
is a strong connection between the two aspects since disordered regions are more dynamic than 
tightly folded structures.  
HX-MS in epitope mapping:  HX-MS has substantial advantages over other foot-printing methods 
since it can probe the entire protein amide backbone (except proline). HX-MS provides 
information on the conformational dynamics of a protein when exchange kinetics are monitored. 
The extent of exchange reflects changes in protein solvent accessibilities as well as changes in the 
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stability of protein secondary structures (hydrogen bonds). This unique approach has recently been 
used in the biopharmaceutical industry in discovery and development of therapeutic proteins 
including protein conformational changes upon chemical modification, protein aggregation, and 
protein-ligand/ protein-protein interactions in epitope mapping (84, 97-100). The concept of 
applying HX-MS in epitope mapping studies is based on monitoring the changes in hydrogen 
exchange rates in the protein backbone amide hydrogens as a result of formation of antigen-
antibody complex.   
HX-MS experimental design:  
HX experiments are typically performed to compare two states of a protein: a protein free state 
and a protein bound state (protein with antibody). For the protein bound state, both pair of proteins 
including antigen and antibody are mixed and incubated for certain time at a 1:2 molar ratio, 
respectively to ensure proper formation of an antigen-antibody complex. HX is then initiated by 
diluting the stock protein solution (both free and bound state stock solutions) with a large excess 
of D2O buffer and incubated over a period of time at room temperature (25oC). The labeling time 
window usually ranges from seconds to hours. After a predefined period of exchange, the HX is 
quenched using a quench solution. The quench solution is usually maintained at ~ 0oC as well as 
at pH 2.5 where the intrinsic exchange rate is minimal. The quench solution also usually contains 
guanidine hydrochloride, a denaturant, so the protein is unfolded. This unfolding helps in efficient 
subsequent cleavage by pepsin. After quenching the samples, the deuterated samples are then 
passed through an immobilized pepsin column where pepsin cleaves the protein with low degree 
of specificity giving rise to a mixture of redundant or overlapping peptides. This is followed by 
LC separation of the peptides and finally MS analysis to determine the deuterium incorporation 
into the peptides. This approach helps in following, with sufficient spatial resolution (peptide level 
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resolution), changes in solvent accessibility and hydrogen bonding of the antigen due to the various 
perturbations caused by antibody binding. Thus, comparing the exchange kinetics in all of the 
overlapping peptides that span the entire antigen between two states i.e. free and bound, could 
provide information regarding potential epitopes. The binding regions are assigned by identifying 
regions of antigen that becomes protected from HX when an antibody binds to it. For example, 
shown below (figure 2) are representative uptake curves of RTA* (antigen) in presence of an 
antibody, V6B4; on the right, distinct differences in the HX rates are seen in the peptide that spans 
residues 206-218 while no change in deuterium uptake rate is seen in the peptide spanning residues 
56-59. The slow exchange in the peptide spanning 205-217 can be attributed to an increase in 




Figure 2: HX kinetics of two representative RTA* peptides in the presence of an antibody, V6B4. 
Panel (a) contains a peptide spanning residues 56-59, where no differences in HX rate upon V6B4 
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binding. Panel (b) describes the peptide spanning residues 205-217 where the rate of HX was 
substantially lowered.   
One important consideration that impacts the sensitivity of the HX-MS methodology is the need 
to control the extent of back exchange. A good deal of effort has been made to minimize the loss 
of deuterium through back exchange by optimizing solvent pH (101), maintaining the column 
temperatures near 0oC (102), and adding polar aprotic modifiers into the LC eluent (103). Under 
these optimal conditions one can minimize the extent of back exchange to less than 5%. It should 
be noted that obtaining an exact deuterium uptake value is not necessary in the case of epitope 
mapping which involves differential HX measurements since both the experiments (free and bound 
state) are conducted under the same conditions and at the same time.  
                 It is quite common to use more than one method in epitope mapping. In Chapter 2 along 
with HX-MS we used competition ELISAs as an orthogonal method to identify the binding sites 
of VHHs that are specific to RTA*. In our other papers we have used HX-MS to support crystal 
structures of RTA* in complex with antibodies. (Rudolph et.al; Protein engineering, Design and 
Selection, 2018 submitted). Recent advancements in HX-MS hardware (enabling high throughput) 
and software has enabled the use of HX-MS as a robust tool in charactering therapeutic proteins 
including epitope mapping. Several other technological developments in HX-MS can be done to 
further improve its performance and benefit epitope mapping experiments. For instance, coupling 
HX-MS with the electron-transfer dissociation (ETD) technique can help in attaining high 
resolution epitope mapping at a single residue level. Minimizing deuterium back exchange to 
negligible level could enhance the sensitivity of the method. Improved sequence coverage 
especially in the case of large proteins (>150 kDa) could help in characterization of potential 
epitopes. Nevertheless, among various orthogonal approaches, HX-MS has become one of the 
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most efficient methodologies for studying protein non-covalent interactions including protein-
protein (epitope mapping) and protein–small molecule interactions.   
Using HX-MS we have extensively conducted epitope mapping studies of RTA* using a large 
collection of ricin specific monoclonal antibodies and VHHs (68, 77, 104). To date, we have 
mapped nearly ~70 antibodies including VHHs and monoclonals as shown in the table below. 
Antibodies are classified into their respective clusters using orthogonal approaches including 
crystallography, competition ELISA and HX-MS. 
Cluster mAb VHH 2o structure 
I PB10, R70, WECB2 JIV-F5*, JIV-G12* (and its variants S1,T1,F2), JIY-
A7*, JIY-E3, JIY-E5*, JIY-G11*, JNM-B5, JNM-
E4, JNM-F8*, JNM-G4, JPF-E8, V6F6, V7F8, 
V7H10, V8D5 
helix B, strand h 
I-II  JIY-D9, JIY-D10*, V2B8, V6A2 helix D, strand h 
I-III  JNM-A11, V1B11, JPF-A9*, V6D8, V6F12, V6H6 helix C, strand h 
I-III-IV  V7H7 helix B, C, G 
I-IV  JNM-C12, V7D12  
II SyH7, PA1, TB12, 
PH12, WECH1, LE4, 
CH1, SW1, 6C4 
JIY-E1*, V1C7*, V1C7_G29R, V2B9, V2E8, V5C1, 
V5C1_R29G, V5E1*, JPD-H11, JPF-H2 
helix A, C-G, 
strand d-e 
II-III  JNM-D1 helix C, G 
III IB2 
 
JIV-F6, V1B10, V1D3*, V1G6, V2A11*, V2G10*, 
V5A2, V6A6, V6A7*, V6B4 , V6C4, V6D4*, 
V6G10, V6G12, V6H8*, V7C8, V8C7, V8E6 
helix C, G, 
strand i-j 
 








Underline indicates the mAb &VHH epitopes that have been resolved by HDX; * indicates the VHH –
RTA* structures that have been solved by X-ray crystallography; Red are strongly neutralizing antibodies. 
In this dissertation, the work focusses mainly on cluster III VHHs and any other VHHs that are 
related to cluster III including VHHs that are classified as cluster I-III, I-III-IV and II-III. 
 In chapter 2, we have used HX-MS to study protein-protein interactions while in chapter 3 we 
used it for studying protein-small molecule interactions i.e. interaction of polyanions with 
fibroblast growth factor-1 (FGF-1). 
FGFs: The mammalian fibroblast growth factors (FGFs) are a family of twenty three secreted 
proteins that interact with four signaling tyrosine kinase FGF receptors (FGFRs). These FGFs, 
FGF1-FGF10 and FGF16-FGF23 are grouped into six subfamilies based on differences in 
sequence homology and phylogeny (105). The unassigned FGFs, FGF11-FGF14, share a high 
sequence identity with the FGF family but do not activate FGFRs and hence are not considered 
actual members of the FGF family (106). FGFs are mitogenic and play a primary role in the 
regulation of angiogenesis. They are involved in a variety of physiological events including wound 
healing, organogenesis, tissue maturation, brain patterning etc. Most FGFs are specifically 
distinguished by their ability to bind heparin and hence are designated as heparin-binding growth 
factors. In fact, signal transduction requires association of FGF with FGFRs and heparin sulfate 
(HS) proteoglycan in a specific manner on the cell surface. FGF-1, also known as acidic fibroblast 
growth factor, is unique in that it activates/stimulates all FGFRs. Thus, FGF-1 is considered to be 
a “pan-FGFR activator” and as a result a broad specificity human mitogen (107, 108).  
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It is well established that HS involvement is required for FGF receptor signaling (109-111). 
Numerous studies have reported the crystal structures including binary complexes of FGF-heparin 
(112, 113), FGF-FGFR (114, 115). However, solving the crystal structure of FGF1-FGFR-HS 
ternary complex has provided the structural basis for the role of HS in FGF signalling (116). 
Crystal structure of the ternary complex revealed that one heparin (decasaccharide) molecule links 
two FGF-1 molecules in which each of them binds to a single receptor, thus making it a 
heteropentameric assembly.  In other words, the complex is considered as two 1:1 FGF1-FGFR 
complexes associated through interaction with heparin. The role of HS is not just limited to FGF-
1 signalling but also plays a key determinant in the pharmacokinetic properties of FGF-1 (117, 
118). For instance, increased tissue levels of HS restrict the distribution of signalling molecules 
such as FGF-1, and may play a role in pattern formation in embryogenesis. On the other hand, 
decreased levels of HS in the vasculature aid in long range transport of such signalling molecules 
(119).   
Crystal structure of FGF-1:  FGF-1 is one of the better characterized members of the FGF family. 
FGF-1 adopts a β-trefoil fold, exhibiting a pseudo-three-fold (i.e. C3) cyclic symmetry at the 
tertiary structure level (120-122). It is composed of three repeating trefoil-fold subdomains which 
are of approximately 40-50 amino acids in length. Each subdomain is composed of a pair of 
antiparallel β-hairpin like structure. Therefore, FGF-1 has a total of 12 β-strands (numbered# 1-
12) and 11 reverse turns (numbered# 1-11) (figure 3). Turns are the principal structural elements 
that allow 180o changes in the polypeptide chain direction and are responsible for adoption of a 
globular protein architecture.  FGF-1 contains a cluster of basic residues in the last two-thirds of 
the third trefoil-fold subdomain forming a dense positively charged patch as shown in Figure 3. 
Although, the higher order (tertiary structure) symmetry of FGF-1 consists of three repeating 
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subdomains, the primary structure of FGF-1 is highly asymmetric i.e. only one amino acid is 
conserved among the three repeating subdomains. This asymmetrical sequence may reflect not 
only genetic drift but also explains the distribution of folding and functional regions 
asymmetrically distributed in the primary structure.     
 
Figure 3: Left panel: Ribbon diagram of FGF-1 (PDB: 1JQZ) oriented along the C3 (three fold) 
axis of rotational symmetry. β-strands (#1-12) and turns (#1-11) in the three subdomains are 
labelled. The C-terminus region that is rich in positively charged amino acids is shaded green. 
Right panel: FGF-1 is rotated 180o to indicate the positive charge rich C-terminus subdomain. 
Heparin and membrane bound heparin sulfate proteoglycan (HSPG) which consist of large 
negative charge density are known to bind to specific cluster of positively charged amino acids in 
both the C–terminus as well the N–terminus region. Numerous investigators employing a wide 
range of methods have identified the regions that are associated with HS binding and receptor 
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binding functionality in FGF-1. Several molecular structures, including seven x-ray and two NMR 
(PDB accession 1E0O, 1DJS, 1RY7, 2ERM, 1HKN, 1RML, 1AFC, 1EVT and 1AXM) of FGF-1 
are solved in complex with receptor and/or heparin analogues and have been used to identify the 
structural details of the regions of FGF-1 associated with heparin and receptor binding.  The above 
structural data has been validated using a large number of functional studies (including point 
mutations, deletions, chemical modifications and peptide binding competition studies) in 
combination with affinity chromatography, surface plasmon resonance and analytical 
ultracentrifugation (123-126). X-ray crystallography studies have revealed the core HS-binding 
region on FGF-1, in which HS interacts with amino acid residue 18 (Asn18) as well as the C-
terminus region spanning residues from 112-128 of FGF-1 (116, 127).  
FGF-1 stability: 
While HS binding is critical for the proper biological functioning of FGF-1, addition of HS to 
FGF-1 also confers stability against thermal and chemical denaturation as well as proteolysis (128-
130). Thus, heparin inclusion in the formulation of FGF-1 improves its potency, stability, and 
storage (128). Many potential clinical applications of FGFs have been suggested due to their wide 
range of receptor- mediated biological activities. In particular, their effect on the process of wound 
healing has generated significant interest (131, 132). For an efficacious formulation of FGF-1, one 
of the important aspects to be considered is its conformational stability against thermal unfolding 
since it is known that FGF-1 unfolds at physiological temperature in the absence of a stabilizing 
polyanion (133) . In addition to the well-known protection of FGF-1 by HS, a surprising number 
of polyanions, including sulfated and phosphorylated compounds, have also been shown to induce 
physical stability (134). Subsequently, it was found that the structural specificity of the ligand 
required to stabilize FGF-1 against heat induced aggregation was weak. A vast variety of 
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negatively charged bio-polymers (nucleic acids, phosphorylated proteins, and homopolymers of 
acidic amino acids), sulfated polymers (heparins, chondroitins, dextran etc.) and even smaller 
sulfated and phosphorylated organic molecules are also able to inhibit thermal induced aggregation 
of FGF-1. The common feature among these agents is the presence of at least one or more highly 
negative charge density regions. It was also found that the level of ligand sulfation/phosphorylation 
is critical for inducing FGF-1 stability. Increasing the sulfation/phosphorylation level dramatically 
enhances the thermal stability of FGF-1(134).   
How do polyanions stabilize FGF-1? What are the binding sites of these polyanions? 
The above questions have been addressed previously using crystal structures and NMR using 
heparin and its analogues. While crystallography is the mother of all techniques for identifying the 
binding sites, it cannot follow the conformational dynamics of the protein. To this end, NMR has 
been used and was successful in identifying the binding sites of heparin and heparin analogues. 
Herein, we used HX-MS to address the above two questions. We focused on four polyanions 
including two sulfated and two phosphorylated molecules. In particular, we have studied two 
sulfated molecules including heparin and low MW heparin since sulfation levels are critical for 
enhancing the protein’s thermal stability as well as two phosphorylated molecules including phytic 
acid and ATP (small organic phosphorylated molecules).  
Briefly, our study has revealed all the polyanions invariably have the same binding sites on FGF-
1. As expected, heparin (carries high negative charge density compared to other three tested 
molecules) has shown strong protection i.e. stronger interaction compared to the others. Also, the 
entire FGF-1 has shown slow HX in the presence of all polyanions implying the conformational 
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Ricin toxin is a member of the ribosome-inactivating protein family that includes Shiga, verotoxin 
and abrin (1). Ricin toxin is a 65 kDa glycoprotein that is comprised of two subunits, RTA and 
RTB, joined by a single disulfide bond (2, 3). RTA, which possesses the enzymatic site, inactivates 
eukaryotic ribosomes by cleaving the highly conserved adenine residue (A4324) within the sarcin-
ricin loop of 28S ribosomal RNA (4, 5). RTB, ricin’s binding subunit, is a Gal- and GalNAc-
specific lectin which mediates toxin entry into the mammalian host cell (6). Ricin can effectively 
intoxicate all known eukaryotic cell types. 
Five residues (Tyr80, Tyr123, Glu177, Arg180, Trp211) play critical roles in RTA’s enzymatic 
activity (7). The active site in RTA consist of residues located in various secondary structure 
elements including helices C, E and G. At the tertiary structural level, RTA assumes a globular 
fold that can be divided into three distinct folding domains (2, 3). Folding domain I (residues 1-
117), conserved among other ribosome inactivating protein toxins, consists of eight β-strands (a-
h) and two α-helices (A and B). Folding domain II (residues 118-210) is dominated by five α-
helices (C-G). Folding domain 3 (residues 211-267), which has two β-strands (i and j), interacts 
with RTB through hydrophobic interactions as well as a disulfide bond (2, 3). Structurally, most 
of the active site falls within folding domains 1 and 2. Residue Y80 is located in the turn connecting 
strands e and f. Residue Y123 is located in the N–terminus of helix C. Residues Glu177 and 
Arg180 are located in the C-terminus of helix E. Finally residue Trp211 is located in the center of 
helix G. In the folded RTA, all the above mentioned residues are placed close to each other forming 









Figure 1. Crystal structure of RiVax a) left panel shows the residues that constitute active site located in various 
α-helices including C, G and E; right panel shows the top view of toxin’s active site that form a shallow pocket 
like structure. The colored residues correspond to the following: green, Tyr80; red, Tyr123; blue, Glu 177; 
cyan, Arg 180; orange, Trp 211.  (b) Location of the epitope of IB2 on RiVax (PDB ID: 3SRP). The color shading 
corresponds to the following; deep blue, strong protection; light blue, intermediate protection; grey, non–
significant. The data are taken from our previous work (24). 
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Despite a good understanding of the toxin’s structure and function, there is no approved vaccine 
for ricin toxin. A leading vaccine candidate is RiVax. RiVax is a full-length derivative of RTA 
that has two point mutations aimed at eliminating enzymatic activity (Y80A) as well as vascular 
leak syndrome (V76M) associated with ricin toxicity. X-ray crystallography has shown that RiVax 
is very similar to RTA, indicating that the substitutions do not alter the tertiary structure of RTA 
(7). Toxin-neutralizing antibodies target limited “hot spots” on RTA’s surface that we have 
designated epitope clusters I-IV (8-10). Cluster I, defined by mAbs PB10, R70 and WECB2, 
encompasses α-helix B and β-strand h. Cluster II is recognized by nine mAbs, most notably SyH7, 
that target two distinct sub-clusters on the backside of the toxin: one sub-cluster defined by the 
loop connecting α-helices F and G, the other encompassing two loops, bridging β-strands d and e 
and α-helices D and E. Cluster IV is defined by GD12 and JD4, which bind to β-strands b-d [(11), 
G Van Slyke et al, manuscript submitted].  
The mAb IB2 defines Cluster 3. IB2 was first reported by O’Hara et al (8) where we relied 
on competitive binding assays to identify its epitope location. We found its epitope to be distinct 
from that of known toxin neutralizing antibody epitopes that fall in cluster I and II, however, we 
could not determine the exact epitope site of IB2 in that report. IB2 was later studied in other 
papers (12) where we show that it interferes with retrograde transport and protein disulfide 
isomerase (PDI) interactions with ricin (13). IB2 doesn’t bind to RTA on microtiter plate 
presumably due to local conformational changes. In other words, the cluster is highly 
conformationally specific. 
To localize IB2’s epitope, we performed hydrogen-exchange mass spectrometry (HX-MS).  Of 
late, HX-MS has been increasingly used in epitope mapping studies (14-16). RiVax in the presence 
of its cognate antibody shows a decrease in deuterium uptake in the regions where antibody binds 
39 
 
to. In other words, protection (from deuterium uptake) is observed in the regions where antibody 
makes contact.  More details in identifying an epitope region using HX-MS method is described 
in the result section. Analysis revealed that IB2 strongly protects α-helices C (residues 119-135) 
and G (residues 205-217), as well as a short region (residues 249-255) in RTA’s C-terminus 
(Figure 1b) (11). Beyond IB2, very little is known about so-called cluster 3, even though it is 
clearly a target of toxin-neutralizing antibodies. 
To better understand cluster 3, we recently screened camelid antibody library for VHHs 
that competed with IB2 (17). We identified nine. In a separate screen we identified an additional 
unique VHHs that competes (D. Vance. C. Shoemaker, N. Mantis, manuscript in preparation). 
Therefore, we have a collection of 21 VHHs that are operationally defined as being with Cluster 3. 
In this study, we localized by HX-MS the epitopes of all 21 of these VHHs. We found that the 21 
VHHs fall within one of four distinct but overlapping subclusters (3.1-3.4) that share at least one 
secondary element contacted by IB2.  Only two of the 21 VHHs, V6D4 and V1D3, have appreciable 
toxin-neutralizing activity (TNA), which we speculate is due to their epitope specificity along with 
strong binding affinity to toxin. Evidence points to helix G being important in neutralizing activity. 










Results and Discussion 
Identification and characterization of Cluster 3 VHHs.  We identified a total of 21 VHHs that were 
partially or completely unable to bind to ricin that had been captured by IB2 (Figure 2).  The 
predicted amino acid sequences of the 21 VHHs suggested that they represent eleven B cell lineages 
based on CDR3 similarity: five unique VHHs and 16 that fell into one of six sequence families 
(Table 1, Figure S1). The binding kinetics of each VHH for ricin was determined by surface 
plasmon resonance (SPR).  Twelve of the 21 VHHs had dissociation constants (Kd) of greater than 
1 nM, while nine had dissociation constants ranging from 200-996 pM (Table 2).  When tested in 
a ricin cytotoxicity assay, only V6D4 (IC50, 200 nM) and V1D3 (IC50, 80 nM) had demonstrable 
toxin-neutralizing activity (TNA). Seven other VHHs had Kds comparable to V6D4 and V1D3 but 
did not have TNA, indicating that occupancy (not just binding affinity) on RTA impacts ricin 
toxicity.  For that reason, we sought to localize the epitopes on RTA recognized by each of the 21 
VHHs. The epitopes recognized by JNM-D1 and V1B11 were previously been defined by 
hydrogen-exchange mass spectrometry (HX-MS) analysis (17). We therefore examined the 









Table 1. VHH Families based on CDR3 similarity 
Family Members 




V6A6 V6A7, V6G10, V8C7, V8E6 
V6D4 V6B4 
  
Unique JNM-A11, JNM-D1, V1B11, V5A2, V7H7 
a
, underline indicates VHHs with toxin-neutralizing activity 
 
 
Table 2. VHH Binding Affinities and TNA  
VHH IC50a KDa konb koffc 
JIV-F6 - 1.860 1.94E+05 3.61E-04 
JNM-A11 - 0.200 4.45E+05 8.92E-05 
JNM-D1 - 1.190 1.80E+05 2.15E-04 
V1B10 - 0.917 8.29E+04 7.60E-05 
V1B11 - 8.840 2.76E+04 2.44E-04 
V1D3 80 0.460 3.15E+05 1.45E-04 
V1G6 - 5.340 3.05E+04 1.63E-04 
V2A11 - 1.820 2.97E+04 5.41E-05 
V2G10 - 1.160 8.48E+04 9.84E-05 
V5A2 - 1.460 2.15E+05 3.14E-04 
V6A6 - 0.996 5.06E+05 5.04E-04 
V6A7 - 1.760 7.70E+04 1.36E-04 
V6B4 - 0.652 1.70E+05 1.11E-04 
V6D4 200 0.224 1.44E+05 3.22E-05 
V6D8 - 1.130 2.14E+05 2.41E-04 
V6F12 - 1.210 1.80E+05 2.17E-04 
V6G10 - 1.270 1.77E+05 2.24E-04 
V6H8 - 1.150 6.63E+04 7.66E-05 
V7H7 - 0.507 1.65E+05 8.36E-05 
V8C7 - 0.597 1.58E+05 9.40E-05 
V8E6 - 0.830 1.26E+05 1.04E-04 
























































































































Figure 2. Competition assay to assign VHHs to Cluster 3. Ricin was captured on immunoplates either by mAb 
IB2 or the anti-RTB mAb SylH3. VHHs were then bound to ricin and detected. Normalized % binding was 
calculated as 100*(AIB2-Ricin/ASylH3-Ricin). VHHs along the x-axis are representative of Cluster I (JIV-F5), Cluster 
II (JIY-E1), Cluster 3 Sub-cluster 1 (V5A2-V6G10), Cluster 3 Sub-cluster 2 (V6D8-V7H7), Cluster 3 Sub-
cluster 3 (V6D4), and Cluster 3 Sub-cluster 4 (JNM-A11). 
 
Epitope mapping by HX-MS. We performed HX-MS analysis on RiVax in complex with each of 
the VHHs at five exchange times between 13 s and 24 h, using previously established protocols 
(Toth 2017). For the labeling studies, VHHs were present at a 2-fold molar excess to favor complex 
formation. VHH contact points on RiVax were assigned based on reduced (slower) HX exchange 
for peptides in the presence of VHH compared to with RiVax, as described in detail in Toth et al. 
(2017). For example, in the presence of V6B4 the HX rate in the peptide corresponding to RiVax 
residues 56-59 was unaltered, whereas there was much slower exchange observed for peptide 
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corresponding to residues 205-217 (Figure 3). Slower exchange is attributed to direct protein-
protein interactions, which in the case of antibodies reveals epitopes. We have observed elsewhere 
that increased protection can also result from allosteric effects (11, 17). 
 
 
Figure 3. Hydrogen deuterium exchange kinetics of two representative RiVax peptides in presence of V6B4. A) 
Peptide 14 (56-59), where the HX rate was not affected by association with V6B4. B) Peptide 94 (205-217) where 
the rate of HX was substantially slowed by V6B4. 
 
Upon completion of HX-MS analysis of all 21 VHHs, we found that Cluster 3 VHHs 
grouped within four sub-clusters (3.1-3.4) (Table 3, Table S1; Figure 10). Subcluster 3.1 involves 
contact with α-helices C and G, a profile very similar to IB2 (the mAb that defines cluster 3).  
Subcluster 3.2 encompasses α-helices B, C and G, while subcluster 3.3 covers α-helices B and G, 
but not α-helix C. Finally, sub-cluster 3.4 encompasses α-helices C and E, but not G.  Each of these 





Table 3. RiVax peptides, residues, and secondary structures protected by Cluster 3   
VHHs. 
  Strong and Intermediate Protected Elements a 
VHH Subcluster Peptides Residues Secondary Structure(s) 
V6B4 3.1 48-51 119-133 -helix C 
  91-102 205-217 -helix G 
  132-134 249-255  
     
V1D3  54,55 127-135 -helix C 
  91 205-210 -helix G 
  112-116 226-243 β-strands i, j  
  132-134 249-255  
     
V6D8 3.2 35-39 92-107 -helix B 
  49-54 123-135 -helix C 
  102 211-217  α-helix G 
  129-134 247-255  
     
V6F12  35-40 92-107 -helix B 
  47,49 118-126 -helix C 
     94,97,100,102-103 205-217 -helix G 
  132-134 249-255  
     
V7H7             35-39 92-107 -helix B 
  49 123-126 α-helix C 
  94-95,97-98,100,102 205-217 α-helix G 
  129-131 249-255  
     
V6D4 3.3 35-37,39 92-107 -helix B 
  102 211-217 -helix G 
  132-134 249-255  
     
JNM-A11 3.4 45,46 108-122 β-strand h 
  49-51 124-133 -helix C 
  70,71 162-168 -helix E 





Subcluster 3.1: Sixteen of the twenty one VHHs shared an HX-MS profile involving 
contact with α-helices C and G, which we refer to as subcluster 3.1 (Table 3; Figures 4-5; Table 
S1; Figures S2, S3). While the HX-MS profiles of the VHHs within 3.1 were qualitatively similar, 
there were quantitative differences that may be significant in terms of neutralizing activity. For 
example, V1D3, one of the two VHHs with TNA, had a binding pattern virtually identical to IB2 
in that it strongly protected α-helix C (peptides 54-55, residues 127-135) and the C-terminus region 
(peptides 132-134, residues 249-255).  Moreover, V1D3 demonstrated intermediate protection of 
α-helix G (peptide 91, residues 205-210), as well as strands i and j (peptides 112-116, residues 
226-243).  
In contrast, V6B4 strongly protected RiVax residues 119 to 133 (peptides 48-51), corresponding 
to α-helix C, and residues 205-217 (peptides 91 to 102), corresponding to α-helix G (Figure 4a, 
5a) but differed from V1D3 in three respects. First, V6B4 had stronger protection of α-helix G 
than C, as compared to V1D3. Second, V1D3 interacted with β-strands i and j, while V6B4 does 
not, possibility indicating that V1D3 overall contact interface with RiVax is larger than V6B4’s. 
Finally, the patterns of protection in α-helix C are distinct. In case of V6B4, the entirety of α-helix 
C is strongly protected, while in the case of V1D3 it is only the C-terminal end that is strongly 
protected (Figure 4a and 4b). V1D3 also caused intermediate protection in the N-terminal end of 
helix G while V6B4 has protected all of helix G. These differences in helix C and G protection 
could very well account for differences in toxin-neutralizing activity.  Indeed, given the large 
number of VHHs that fall into this sub-cluster, it is possible that there are several different 
orientations of VHH binding that would only be resolved through VHH-RTA co-crystal structures 






Figure 4. Relative levels of protection of RiVax peptides by VHHs in 3.1.  The ∆𝐇𝐗 ̅̅ ̅̅ ̅values for each RiVax peptide 
are shown for VHHs (a) V6B4 and (b) V1D3. The ∆𝐇𝐗̅̅ ̅̅  values are clustered using k-means clustering into three 
categories as follow: deep blue, strong protection; light blue; intermediate protection, and gray, insignificant. 











Figure 5. Epitope regions as identified by HX-MS are mapped onto the structure of RiVax. HX protection 
categories in figure 4 are shown mapped onto the crystal structure of RiVax for (a) V6B4 and (b) V1D3. The 
most relevant secondary structure elements helices C and G and C-terminus regions are labelled. Color coded 







Subcluster 3.2: A total of three VHHs were grouped within sub-cluster 3.2 based on 
common HX-MS profile encompassing α-helices B, C and G (Figures 6-7). For example, V6D8 
strongly protected α-helices B (residues 92-107, peptides 35-39), C (residues 123-135, peptides 
49-54), and G (residues 211-217, peptides 102), plus a short region near the C-terminus (residues 
247-255, peptides 129-134). V6F12 likely derived from the same B-cell lineage as V6D8 (Table 
1, Figure S1). Although the protection profiles of V6D8, V6F12, and V7H7 are similar, the 
magnitudes of protection in the three secondary structural features are distinct. V6D8 and V6F12 
interacted primarily with α-helices B and C, and secondarily with α-helix G. V7H7, by contrast, 
primarily protects several overlapping peptides in α-helix G, and secondarily protects α-helices B 
and C (with the exception of one peptide in α-helix C). In all three cases (V6D8, V6F12, and 
V7H7), contact with α-helix B was corroborated by competitive binding assay with Cluster 1 
mAbs PB10 and WECB2 (DJ Vance, J Tremblay, CB Shoemaker, NJ Mantis, manuscript in 
preparation). Given that α-helix B is a neutralizing “hotspot” on RTA (9, 10, 18, 20, 21), it is a 
little surprising that none of the VHHs in this sub-cluster have any detectable TNA, especially in 











Figure 6. Relative levels of protection of RiVax peptides by VHHs that are classified into subcluster 2 within 
cluster 3 as defined by HX-MS. The ∆𝐇𝐗 ̅̅ ̅̅ ̅values for each RiVax peptide are shown for VHHs (a) V6D8 (b) 







Figure 7. Visual presentation of epitope regions of V6D8, V6F12 and V7H7 on RTA*. HX protection categories 
in figure 6 are shown mapped onto the structure of RiVax for (a) V6D8 (b) V6F12 and (c) V7H7. Secondary 
structure elements including helices C and B as well as strand h and c-terminus regions are labelled. 
Intermediate protection by V6D8 is spread over much of RiVax’s surface and the magnitudes of protection are 
low. Therefore, only strongly protected elements are mapped onto the crystal structure of RiVax. 
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Subcluster 3.3: The third sub-cluster is populated only by V6D4, which has weak toxin-
neutralizing activity (IC50 ~200 nM).  Interestingly, V6D4 appears to have arisen from the same 
B-cell lineage as V6B4 in subcluster 3.1(Table 1, Figure S1). HX-MS analysis demonstrated 
strong protection of α-helix G (peptide 102, residues 211-217) and intermediate protection of α-
helix B (peptides 35-39, residues 92-107). V6D4 also protected short region in the C-terminus of 
RiVax (Figure 8a and 8b).  V6D4 did not protect α-helix C, which differentiates it from 
subclusters 3.1 and 3.2.  We can only speculate that contact with α-helix B coupled with a higher 
affinity for ricin (Kd = 224 pM) is what accounts for V6D4’s neutralizing activity.  
Subcluster 3.4: The fourth sub-cluster is populated by JNM-A11. JNM-A11 strongly 
protects residues in α-helix C (peptides 49-51, residues 124-133), and also intermediately protects 
residues in the N-terminal region of α-helix E (peptides 70 and 71, residues 162-168) and β-strand 
h (peptides 45 and 46, residues 108-122) (Figure 9a and 9b). JNM-A11 is unique among the 
cluster 3 VHHs in that it does not protect α-helix G, possibly because of a different angle of 
approach compared to the other VHHs. The HX-MS protection profile is consistent with 
competition data: JNM-A11 is competed by Cluster I mAbs PB10 and WECB2 and also by the 
Cluster I-II overlap mAb SWB1 (17). JNM-A11 does not neutralize ricin, despite a very strong 
binding affinity (Kd = 200 pM). Since JNM-A11 appears to almost exclusively target α-helix C, 
we would infer that contact with α-helix C alone is not sufficient to affect ricin function.  By 
extension, neutralization of ricin by the sub-cluster 1 VHH V1D3, which targets α-helices C and 






Figure 8. Location of the epitope of V6D4 on RiVax. (a) Relative levels of protection of RiVax peptides by V6D4 
as defined by HX-MS. The image is color coded according to figure 1b. (b) The HX protection categories, as 
shown in panel b, are mapped onto the crystal structure of RiVax Secondary structures including helices B and 












Figure 9. Relative levels of protection of RiVax peptides by JNM-A11 that is categorized into subcluster 4 within 
cluster 3 as defined by HX-MS. (a) ∆𝐇𝐗  ̅̅ ̅̅ ̅̅ values for each RiVax peptide are shown for VHH, JNM-A11. The 
delta HX values are color coded as in Figure 4. (b) The HX protection categories are mapped onto the crystal 






Figure 10. Summary of epitopes within cluster III as identified by HX-MS. The colored rectangle bars denote 
epitopes for subclusters 3.1-3.4. Regions protected by VHHs in various subclusters are shown in linear 
representation of the primary sequence of RiVax, aligned with a cartoon secondary structure. Arrows denote 
β secondary structure and coils indicate helices.  
 
Conclusions and perspectives 
Our analysis concludes that helix G is critical in TNA as both toxin neutralizing VHHs, V1D3 and 
V6D4 epitopes constitute helix G. At this point we are not entirely sure about the roles of helices 
C and G in toxin neutralizing capacity. For example, mAb IB2, a strong neutralizer makes strong 
contact with helix C than G. Similarly one of the two neutralizing VHHs, V1D3 (subcluster 3.1), 
also showed strong binding in helix C than G. In contrast, V6D4 (subcluster 3.3), does not make 
any contact with helix C yet it shows neutralizing capacity. Also, a lot of VHHs we analyzed in 
this report fell in subcluster 3.1, involving interaction with C and G. The fact that all these VHHs 
being as non-neutralizers didn’t help in understanding what role helix C plays. We believe that 
helix C acts as a docking station while interaction with neighboring helix G being critical. 
Ultimately, it could probably be the differences in the angle of contact with the helices C and G 
that could explain the TNA. Also, there could be single amino acid residue contacts that could be 
critical for TNA. Unfortunately, HX-MS would not be able to pick these single residue contacts 
as the deuterium uptake differences in those regions would be minimal such that it is tough to 
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predict whether those differences are a result of allosteric effects or real effects (due to binding). 
We believe solving crystal structures would give deeper insights including understanding the roles 
of helices C and G in TNA, critical single amino acid residue contacts and the angle of contact. 
Towards this end, we started to crystallize antibody-antigen complexes to better understand the 
cluster 3 region on the surface of RTA. For example, we successfully co-crystallized V1D3 with 
toxin and it binds to cluster 3 as revealed by X-ray crystallography (manuscript in prep).     
While subcluster 3.3, which includes neutralizing antibody, V6D4, involves interaction with helix 
B in addition to helix G and could explain for its TNA as helix B is recognized by a number of 
neutralizing antibodies which are characterized in our previous reports.  The subcluster 3.4, JNM-
A11 involves interaction with helix C but has no contact with helix G. JNM-A11, the strongest 
binder (Kd = 200 pM) of all cluster III VHHs we have studied in this report happens to be a non-
neutralizer implying that helix G is important in TNA.  In fact, JNM-A11 binds to helix C and N-
terminus helix E and strand h implies its binding orientation is unique from the rest of the 
subclusters. To further substantiate that, it is the only antibody in our collection that doesn’t shown 
any protection in the C–terminus region of RiVax. In the case of JNM-A11, the binding region 
and C–terminus residues are located exactly on the opposite sides of RiVax.         
It should be mentioned that all the VHHs reported here (with an exception of subcluster 3.4, JNM-
a11) have shown strong protection in C–terminal residues (249-255) of RiVax. This region is 
located in the bottom side of RTA which associates with RTB in the context of the holotoxin and 
hence is not surface exposed. Thus, the strong protection seen in this region is probably due to 
allosteric effect.  
             Another noteworthy feature to mention is that none of the subcluster 3.2 antibodies which 
recognize helix B has TNA. While the binding affinities of V6D8 and V6F12 are in the nanomolar 
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range, on the other hand, V7H7 showed a sub nanomolar binding affinity value (Kd =507pM) 
comparable to the 460 pM dissociation constant of the neutralizing sub-cluster 1 VHH, V1D3. That 
said, other neutralizing VHHs that target α-helix B, such as F5 and E5 have even higher affinities 
of 19 and 190 pM, respectively (10, 18, 22), so perhaps higher affinity than even 507 pM is 
required to neutralize via α-helix B. The differential protection profiles could be a consequence of 
different angles of approach such that V6D8/V6F12 anchor themselves on α-helices B and C, 
while V7H7 targets α-helix G. 
Materials and methods: 
RTA* purification: RTA* was expressed and purified as described in (23). Briefly, the gene 
encoding RTA* was cloned into the pTBSG expression vector which has an N-terminal 6-His 
affinity tag. Plasmid DNA was transformed into the chemically competent E. coli cells BL21 
(DE3)-pRARE. Protein expression was induced by addition of isopropyl B-D-1-
thiogalactopyranoside (IPTG). The His-tag RTA* was then purified using a His-select high flow 
Ni+2 affinity gel, followed by overnight digestion with a His-tagged TEV protease to cleave the N-
terminal His-tag of RTA*. The His–tag cleaved RTA* was then purified from the flow-through of 
a second round of immobilized Ni+2 ion chromatography.  
HX-MS: HX-MS experiments for epitope mapping were conducted as described previously (24). 
Briefly, a LEAP H/DX PAL robotic system was used for sample preparation, mixing and injection. 
For the free RTA*, 4 µl of 20 µM RTA* stock solution was incubated with 36 µl of deuterated 
buffer (10 mM sodium phosphate, 150 mM sodium chloride, pD 7.4). For the bound states, the 
stock solution had a final concentration of 20 µM RTA* and 40 µM VHH resulting in 1:2 molar 
ratio of RTA*:VHH. Four µl of the stock was incubated with 36 µl of deuterated buffer. Samples 
were incubated at 25oC for five HX times between 13 s and 24 h and subsequently quenched using 
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200 mM phosphate-4 M guanidine hydrochloride solution (pH 2.5) held at 0oC. The quenched 
samples were then injected onto an immobilized pepsin column where proteolysis occurs 
overlapping peptides from RTA*. The peptides were desalted using a C18 trap and are separated 
using a segmented gradient with water/acetonitrile/0.1% formic acid on a C18 column (Zorbax 
300SB-C18 2.1 × 50 mm, 1.8 μm particle diameter, Agilent, Santa Clara, CA). The entire LC 
system (immobilized pepsin column, C18 trap and a C18 RP-UHPLC column) was kept in a 
refrigerated cabinet that is maintained at 0OC to minimize back exchange. Nevertheless, the first 
two residues in a peptide generally undergo rapid back exchange (25). RTA* peptides are analyzed 
by an Agilent 6530 series QTOF mass analyzer for their increase in mass i.e. for deuterium uptake.  
Data Analysis  
     The HX-MS data processing was carried out using HDExaminer (Sierra Analytics, CA). A total 
of 138 peptides (see supplementary table 2) that cover the entire sequence of RTA* were analyzed. 
For each peptide, the magnitude of protection from each HX time was averaged and normalized 
to its peptide length to obtain a ΔHX value, ∆HX = HXbound − HXbound, as described previously 
(26). The propagated standard error in delta HX was estimated as described in (26). The 
magnitudes of delta HX values of overlapping peptides that span the entire RiVax are then 
classified using K-means clustering into three categories and were colored as follows: strong 
protection, intermediate protection, no significant protection. For visualization, the HX-MS results 
were mapped onto the crystal structure of RTA*(PDB: 3SRP) (7) using PyMoL (The PyMOL 
Molecular Graphics System; Schrodinger LLC, San Diego, CA). For better visualization purpose, 
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Supplementary Table 1. Summary of HX-MS analysis of fourteen VHHs bound to RiVax 
Table 3. RiVax peptides, residues, and secondary structures protected by Cluster 3 
VHHs. 
  Strong and Intermediate Protected Elements a 
VHH Subcluster Peptides Residues Secondary Structure(s) 
V1B11 3.1 49-54 123-135 -helix C 
  94-102 205-217 -helix G 
  132-134 249-255  
     
JNM-D1  55 130-135 -helix C 
  50-54 123-135 -helix C 
  91 205-210 -helix G 
     
V2A11  49 123-126 -helix C 
  50-53 123-135 -helix C 
  92-103 205-217 -helix G 
  106-116 218-243 β-strands i, j 
  132-134 249-255  
     
V6H8  48-52, 54 119-135 -helix C 
  94,95,97,98,100,102    205-217 α-helix G 
  132-134 249-254  
     
V6A6             48-52, 54 119-135 α-helix C 
  91-102 205-217 α-helix G 
  130-134 247-255  
     
     
V6A7  49 123-126 N-term α-helix C 
  48, 50-52, 54 119-135 -helix C 
  92-100 205-217 α-helix G 
  132-134 247-255  
     
V6G10  49 123-136 N-term α-helix C 
  48,50-52,54 119-135 -helix C 
  92-100 205-217 -helix G 
  132-134 247-255  
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    V8C7  49 123-126 N-term α-helix C 
  48, 50-54 119-135 α -helix C 
  91-102 205-217 -helix G 
  132-134 249-255  
     
V8E6  49 123-126 α-helix C 
  47, 50-55 119-135 α -helix C 
  92-103 205-217 α-helix G 
  129-134 247-255  
     
V1G6  50-54 123-135 α-helix C 
  94,97-98,100,102 205-217 α-helix G 
  109-111 218-232 β-strand i 
  112-113, 115 226-240 β-strands i, j 
  132-134 249-255  
     
V2G10  47, 50-54 118-135 α-helix C 
  55 130-135 C-term α-helix C 
  92-103 205-217 α-helix G 
  111-113 221-240 β-strands i, j 
  132-134 249-255  
     
V5A2  49-53 123-135 α-helix C 
  54,55 127-135 α-helix C 
  91 205-210 α-helix G 
  114 227-240 β-strands i, j 
  112-113,115-116,119 226-243 β-strands i, j 
  132-134 249-255  
     
JIV-F6  54 127-135 α-helix C 
  51-53 123-133 α-helix C 
  91 205-210 α-helix G 
  113-115 226-240 β-strands i, j 
  129-131 249-255  
     
V1B10  54 127-135 α-helix C 
  51-53 123-133 α -helix C 
  91 205-210 α-helix G 
  113,115,116 226-243 β-strands i, j 
  132-134 249-255  






Supplementary Table 2. RTA* peptic peptides 
             Amino acid                    Amino acid                       Amino acid                        Amino acid  
               residue #                         residue #                           residue #                            residue #                          
         
Pep # start end  Pep # start end  Pep # start end  Pep # start end 
1 0 11  36 92 103  71 162 168  106 217 232 
2 12 20  37 92 107  72 165 168  107 217 240 
3 12 24  38 93 99  73 165 171  108 218 225 
4 21 24  39 93 107  74 168 171  109 218 232 
5 25 32  40 102 107  75 169 173  110 220 232 
6 25 37  41 103 107  76 172 181  111 221 232 
7 28 37  42 104 107  77 175 181  112 226 232 
8 33 59  43 104 109  78 178 181  113 226 240 
9 37 59  44 108 117  79 182 186  114 227 240 
10 38 45  45 108 118  80 182 187  115 232 240 
11 38 55  46 108 122  81 182 188  116 232 243 
12 38 57  47 118 122  82 182 190  117 232 248 
13 38 59  48 119 126  83 182 204  118 233 243 
14 56 59  49 123 126  84 187 204  119 233 244 
15 58 61  50 123 129  85 188 204  120 233 246 
16 58 68  51 123 133  86 189 204  121 233 248 
17 60 68  52 123 135  87 189 206  122 240 243 
18 60 69  53 127 133  88 191 204  123 241 244 
19 62 68  54 127 135  89 191 207  124 241 246 
20 69 72  55 130 135  90 195 204  125 241 248 
21 69 73  56 130 151  91 205 210  126 243 248 
22 69 74  57 133 144  92 205 214  127 244 248 
23 70 74  58 134 146  93 205 216  128 245 248 
24 72 79  59 134 151  94 205 217  129 247 253 
25 72 91  60 136 146  95 207 214  130 247 254 
26 73 79  61 136 147  96 207 216  131 247 255 
27 73 91  62 136 151  97 207 217  132 249 253 
28 75 79  63 146 150  98 208 214  133 249 254 
29 75 91  64 147 150  99 208 216  134 249 255 
30 80 91  65 147 151  100 208 217  135 255 267 
31 80 92  66 148 151  101 211 216  136 256 267 
32 84 91  67 152 161  102 211 217  137 257 267 
33 92 99  68 152 164  103 212 216  138 258 267 
34 92 101  69 153 164  104 217 220     











































































Investigating the Dynamics and Polyanion Binding Sites of Fibroblast Growth 


















The fibroblast growth factors (FGFs) are a family of structurally and functionally conserved 
protein ligands that regulate a plethora of developmental processes including mitogenesis, 
angiogenesis, homeostasis and metabolism (1). These growth factors signal by associating with a 
specific tyrosine kinase receptor (FGFR) and heparin sulfate proteoglycans (HSPG) to form a 
ternary complex on the cell surface (2). HSPG aids in the formation of the ternary signal 
transduction complex by linking FGF-1 ligands into a dimer/oligomer that bridges two FGFR 
chains (3, 4). Among the FGF family, FGF-1 is unique in that it can stimulate all FGFRs and is 
consequently a broad specificity human mitogen (5, 6). For the same reason, FGF-1 is termed the 
“universal FGFR ligand” and the molecular basis for its broad specificity is attributed to its 
plasticity in the N terminus region (7).          
        FGF-1 is a member of the β-trefoil family of proteins, characterized by pseudo-threefold 
rotational (i.e. C3) symmetry (8, 9) (Figure 1). The overall structure is described by three repeating 
"trefoil-fold" structural motifs. These motifs are each approximately 42 amino acids in length (with 
some variation in length between the three motifs). Each motif contains four β-strands: two β-
strands of each motif contribute to the overall six-stranded β-barrel architecture, and two β-strands 
of each motif comprise a β-hairpin. These latter three β-hairpins form a triangular arrangement 
that pack against the bottom of the β-barrel. The general organization of the primary and secondary 
structure is shown in (Figure 2). The x-ray crystal structure of FGF-1 has been reported and 
includes a 2.0Å resolution structure of the mature 140 amino acid form (crystallizing in space 
group P21; PDB accession 2AFG)(10), as well as 1.65Å and 1.10Å resolution structures of an N-
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terminal 6xHis-tagged form (both crystallizing in space group C2221; PDB accession 1JQZ and 
1RG8, respectively) (11, 12). In the non-His-tagged form, the initial N-terminal nine amino acids 
are not visible in the electron density; whereas, in the His-tagged form there are crystal packing 
interactions between molecules that structure the N-terminus. In neither crystal form are C-
terminal residues 138-140 visible in the electron density. The binding sites of heparin sulfate (HS) 
on FGF-1 as indicated by crystallographic studies reveals that a high negative charge density HS 
interacts with positively charged amino acids in the N-terminus (residue 18) and C- terminus 
region (residues 112-128) of FGF-1 (3, 13). The binding affinity of FGF-1 for HS diminishes 
significantly on deleting the residues at positions 120-122 on FGF-1 while simultaneously 
increasing its thermal stability, leading to a function\stability trade off (14). 
 
Figure 1.  Ribbon diagram view of FGF-1 (PDB ID: 1JQZ) oriented parallel to the C3 axis of the rotational 
symmetry. The green shaded portion indicates the region that is rich in basic amino acids. Right panel is rotated 




 Studies have also suggested that FGF-1 exhibits a foldability-function trade off (15). φ- value 
analysis has shown that, of the three repeated subdomains, the second half of the first trefoil fold 
subdomain and most of the second one participate in the folding transition state, essentially 
forming a core nucleus during protein folding. In contrast, the third trefoil fold subdomain 
contributes little to the folding transition state (i.e., it folds later in the folding pathway) while 
possessing a rich set of diverse functionalities including HS affinity. 
 
Figure 2. Organization of the primary structure of FGF-1 illustrating the three repeating "trefoil-fold" motifs. 
Mature FGF-1 is 140 amino acids; residue positions 10-137 are consistently structured in difference crystal 
forms of the protein. The 12 β-strands of the overall architecture are identified, as are the N- and C-termini. 
The coloring identifies the three repeating trefoil-fold motifs. 
 
         Although Crystal structures of FGF-1 in complex with heparin and other polyanions have 
been solved and clearly identify the binding regions of HS on FGF-1, this approach provides only 
limited information about the structural dynamics of FGF-1 in solution although crystal 
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temperature factors do provide some indirect information. NMR studies have shown that there is 
an overall decrease in flexibility of FGF-1 (with the exception of a few residues) upon binding by 
heparin analogues (16, 17).  
         Hydrogen-deuterium exchange coupled with mass spectrometry (HX-MS) has the capability 
of monitoring the back bone dynamics of a protein molecule. Proteins upon incubation in D2O 
solvent exchange their labile hydrogens with deuterium. The hydroxyl, amine and carboxyl of the 
amino acid residue side chains exchange rapidly and revert back to hydrogen upon exposure to 
H2O during an LC separation. Unlike the side chain hydrogens, many of the amide protons 
exchange slowly. The differential rates observed provide a measure of the dynamic exposure of 
different regions of the backbone except for proline which doesn’t possess an amide hydrogen.  
Regions that are more flexible (e.g. loops, turns) exchange rapidly compared to regions that are 
more rigid (α-helix and β-sheets). A major strength of hydrogen exchange studies lies in its ability 
to compare two states of a protein (e.g. in the absence and presence of a ligand). 
         Several studies have been performed using HX-MS to investigate the effects of salts, 
particular compounds, antimicrobial agents and aggregation on the conformational dynamics of 
proteins including monoclonal antibodies (18-21). Using HX-MS, we have previously reported the 
location of the binding sites of numerous antibodies including monoclonal and single domain 
antibodies (VHHs) on a ricin toxin subunit vaccine antigen RTA
*(22-24). Here, we use HX-MS to 
investigate the dynamics of FGF-1 as well as the binding sites of various polyanions including two 
different forms of heparin and phosphate-containing compounds including ATP and phytic acid. 
        Studies have shown that heparin consisting of at least four monosaccharide units is necessary 
to stabilize FGF-1 from thermal unfolding (25). In addition to this observation, a broad variety of 
anionic species including phosphorylated compounds have been found to bind and stabilize FGF-
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1 in vitro (25, 26). It has been established by crystal structures (PDB accession 1E0O) that heparin 
binds primarily to the C-terminal region of FGF-1. It has also been shown that this heparin binding 
region folds after crossing the barrier during protein folding which provides a basis for a foldability 
and functional trade off in FGF-1 (15).  
        Using HX-MS, along with identifying the binding sites of various polyanions on FGF-1, we 
also examine the dynamics of FGF-1 alone at the peptide level which is in turn narrowed down to 
a residue level using redundant peptides that contains overlapping residues. This is compared to 
the B-factors of the main chain amides from solved FGF-1 crystal structures. Although 
crystallographic B–factors are derived from the protein in a solid state, they can be expected to 
reflect internal steric factors and have some relationship to solution protein dynamics. 
Approximately half of the main chain amides of FGF-1 are in solvent inaccessible environments. 
The location of solvent excluded main chain amides, and their associated hydrogen-bonding main 
chain carbonyl partner, are shown in Figure 3. In HX experiments, it is generally this set of solvent 
excluded main chain amides that can potentially be protected from rapid exchange. Rapid HX 
among this set of solvent excluded main chain amides indicates unimpeded solvent penetration 










Figure 3. Solvent-excluded main chain amides (Gray) in FGF-1 as determined from the X-ray crystal structure 
(gray background, white font). The arrows indicate the hydrogen-bonding partner (with arrow head indicating 
a main chain carbonyl acceptor). 
 
 
Materials and Methods: 
Materials: LC-MS grade water, acetonitrile and 0.1% formic acid in water were obtained from 
Fisher Scientific (Fair Lawn, NJ). Deuterium oxide (99+%D) was purchased from Aldrich. The 
anhydrous form of sodium phosphate dibasic and sodium phosphate monobasic monohydrate were 
obtained from Research Products International (Mt Prospect, IL). Heparin (Average MW: 13.5kDa 
- 15kDa) was purchased from Calbiochem. Low MW heparin (Average MW: 5.5kDa - 6.5kDa) 




Expression and purification of His-tag FGF: N-terminus His tag FGF-1 was expressed and 
purified as previously described in (11). An extinction coefficient of E280nm (0.1%, 1 cm) = 1.26 
was used for concentration determination. 
Hydrogen exchange mass spectrometry: For the unliganded state, the stock solution of FGF-1 was 
diluted to 0.58mg/mL using 6mM phosphate buffer containing 150mM NaCl at pH 7.4. For the 
polyanion bound state, the stock solutions of FGF-1 and polyanion (Heparin and Low MW 
heparin) are diluted to 0.58 mg/L and 0.116 mg/mL (1:0.2 by weight of FGF-1) respectively. In 
the case of phytic acid and ATP, the FGF-1 and ligand were diluted to 0.58mg/L and 1.16mg/mL 
(1:2 by weight) respectively. In terms of molar ratios, for phytic acid and ATP bound states the 
protein was at a [FGF-1]/polyanion molar ratio of 0.02 and 0.015, respectively. For heparin and 
low MW heparin bound states, the [FGF-1]/polyanion molar ratio are 4 and 2 respectively since 
increased concentration of those polymers inhibited FGF-1 ionization confounding mass 
spectrometry analysis. HX-MS experiments were performed using a QTOF mass analyzer (Agilent 
6530, Santa Clara, CA) with a three pump LC system (Agilent 1260, Santa Clara, CA). An H/DX 
PAL robot (LEAP Technologies, Carrboro, North Carolina) was used for sample handling, 
preparation and injection. To initiate the HX process, 4µL of  protein stock was diluted at a 1:10 
ratio with 36 µL of labeling buffer (6 mM sodium phosphate containing 150 mM NaCl at pD 7.3)  
containing either no polyanion (free state) or with polyanion (bound state) prepared in deuterium 
oxide. The reaction mixture was then incubated at 15oC for six time periods of 13, 100, 1000, 
10000, 30000 and 86400 s prepared in triplicate. Thirty µL of the labeled reaction mixture was 
then transferred and mixed with 30µL of quench buffer (4 M Gdn-HCl, 0.2 M sodium phosphate, 
pH 2.5) at 0 °C for 60 s to stop the exchange process. Fifty five uL of the quenched sample was 
then injected into the 100 μL sample loop of a refrigerated column compartment connected to an 
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Agilent 1260 infinity series LC, in-house built immobilized pepsin column, a peptide desalting 
trap, and a C18 column (Zorbax 300SB-C18 2.1 × 50 mm, 1.8 μm particle diameter, Agilent, Santa 
Clara, CA). The temperature of the column compartment was maintained at 1oC to minimize the 
extent of back exchange. Peptides were eluted using an LC method that was described previously 
(22). To minimize the peptide carry over in the immobilized pepsin column from previous runs, 
the pepsin column was washed between each HX run using a procedure described previously (27). 
The extent of deuteration in each peptide was measured using a Q-TOF mass spectrometer, 
equipped with a standard electrospray ionization source operated in positive mode. Collision 
induced dissociation and MS/MS analysis were used to generate a peptide map of FGF that covered 
100% of the FGF sequence with 90 peptides. The peptides are numbered sequentially from the N-
terminus to the C-terminus (see Supplementary Table S1). 
Data analysis: HD Examiner 2.1 software (Sierra Analytics, Modesto, CA) was used to analyze 
the HX data. For backbone flexibility, we quantified the fraction of exchange after 13s (the shortest 
time point possible with our system) as described previously (18). For mapping the binding site, 
the deuterium uptake of the peptides at each time point was exported from HD Examiner. For each 
peptide, information from all time points was combined into a single ∆HX̅̅ ̅̅  value representing the 
average difference in deuterium uptake between bound and free states, normalized for peptide 






        (1) 
where nHX is the number of HX labeling times, Dmax is the theoretical maximum deuteration, ?̅?𝑎,𝑖 
is the average mass of the peptide in the bound state at the ith HX timepoint, and ?̅?𝑏,𝑖 is the average 
mass of the peptide in the free state at the ith HX timepoint. For each peptide, Dmax was considered 
to be the total number of residues in the peptide minus the number of proline residues and the first 
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two N-terminal residues. The absolute ∆HX̅̅ ̅̅  values of all the peptides were then pooled and an 
algorithm employing K means clustering was run to classify the data set into two clusters. We then 
used the following classification system to define protection sites on FGF-1. Cluster one peptides 
that have strong negative ∆HX̅̅ ̅̅  values are defined as strongly protected sites on FGF, while cluster 
two as weak and non-significant. The strong protection category reflects polyanion binding, while 
intermediate/insignificant protection is considered to reflect allosteric effects and structural 
changes. Overlapping residues that fall in both strong and weak protection classifications were 
considered strongly protected. The standard error in ∆HX̅̅ ̅̅  was then considered to be as indicated 
in equation 2 below, an analysis based on propagation of the standard error in triplicate 
measurements through the ∆HX̅̅ ̅̅  calculations. To set the confidence interval, we have taken a "3σ" 
confidence interval (±3 × 𝜀ΔHX̅̅ ̅̅ ).We used the following coloring system with the crystal structure 
















            (2) 
where (𝑛rep = 3) triplicate data, 𝑠𝑎,𝑖  𝑎𝑛𝑑 𝑠𝑏,𝑖  𝑎𝑟𝑒 standard deviation of replicates, s in state a 
and state b respectively at the ith time point, nHX is the number of HX labeling times and Dmax is 
the theoretical maximum deuteration.  
Heat map for the change in HX of FGF-1 alone for buried amide positions: This study 
characterizes a series of 90 peptides generated by a pepsin digest of FGF-1 after HX. The set of 
90 peptides spans the entire FGF-1 primary structure; however, assigning HX protection to specific 
amino acid positions is not straightforward since individual peptides span multiple amino acid 
positions, and individual amino acid positions can be included in more than one peptide. It should 
be possible, however, to generate position-specific data by alignment of the 90 peptides to the 
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primary structure and then averaging the values for the set of peptides that span specific amino 
acid positions. Supplementary Fig 1 shows how this calculation is performed for the data in Fig. 
4A. The peptides are color coded by a "heat map" that indicates their experimentally-derived 
%HX. This heat map is calculated so that BLUE indicates the lowest observed HX and RED the 
greatest. As an example of the residue position calculation, peptides 11-16 overlap the position of 
Thr34; thus, the %HX for this position is the average value for this set of peptides (or 19.0%). For 
FGF-1 the resulting average %HX values for each buried amide position span a low of 4% (e.g. 
Phe132) and a high of 55.8% (Ser47). For heat map coloring purposes to communicate these 
results, this range of values is normalized to span a Blue (4%) to Red (55.8%) scale. Due to the 
primary amine conversion at the first position of a peptide, and a corresponding influence upon 
HX for the second position (28), the first two positions of each peptide are "greyed-out" in 
supplementary Figure 1 - indicating that no HX information is available at these positions. Thus, 
the %HX cannot be assigned for a small number (e.g. positions 23, 24, 74, 75, and 118) of the total 
set of buried amides; however, for all other buried amide positions an average %HX can be 
assigned (along with a corresponding heat map color). 
Heat map for the change in hydrogen exchange of FGF-1 for buried amide positions in the 
presence of heparin: Figure 10 shows how this calculation is performed for the data in Figure 8A. 
This heat map is calculated such that BLUE indicates an increase in HX protection and RED no 
change. As an example of the residue position calculation, peptides 11-16 overlap the position of 
Thr34; thus, the ∆HX̅̅ ̅̅  for this position is the average value for this set of peptides (or -0.109). For 
FGF-1 in the bound state with heparin, the resulting average ∆HX̅̅ ̅̅  values for each buried amide 
position span a low of -0.242 (e.g. Lys112) and a high of -0.015 (Cys83). For heat map coloring 
purposes this range of values is normalized to span a Blue (-0.242) to Red (-0.015) scale. The heat 
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map for buried amide positions in the presence of other polyanions including Phytic acid, ATP 
and Low MW heparin was calculated similarly (supplementary Figure 3, 4 and 5 respectively). 
B-Factor Analysis: A non-His-tagged form of FGF-1 crystallized in the P21 space group with 
four independent molecules in the asymmetric unit (2.0Å resolution)(10). An N-terminal 6xHis-
tagged form of FGF-1 crystallized in the C2221 space group with two independent molecules in 
the asymmetric unit (1.65Å resolution) (11). Isotropic B-factors were refined in both crystal 
forms and residue positions 10-137 were ordered in all structures. The average C B-factors for 
positions 10-137 for the six independent FGF-1 structures were calculated and are shown in 
supplementary Figure 2. Crystallographic B-factors are interpreted as indicating the motion or 
local mobility of the individual atoms (larger values indicating greater mobility). Isotropic B-
factors reflect a model describing simple centrosymmetric vibrational motion (appropriate for 
1.65-2.00Å resolution data).  
Results:  
Backbone flexibility of FGF-1 without polyanion ligation: With the aim of using HX-MS to locate 
the contact regions of various polyanions on FGF-1, we first established the backbone flexibility 
of FGF-1 itself. HX was performed on FGF-1 for 13s and quenched before being subjected to 
pepsin digestion and MS analysis as described in materials and methods. Using K-means 
clustering, backbone flexibility values are then classified into three categories: flexible, 
intermediate and rigid. Flexible and rigid regions of FGF-1 are shown in Figure 4A. The peptides 
are numbered sequentially from N to C terminus in all figures unless otherwise specified (Table 
1). The flexible and rigid regions are spread throughout the protein sequence. Flexible regions are 
seen in strands 4, 5 and 7 as well as in turns 4, 5 and 7. These are all located on one side of the 
protein. Another substantial flexible region includes C-terminal strand 12. Rigid regions include 
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strands 2, 3 and 6 as well as turns 2, 3 and 6. Other significant rigid regions include C-terminus 
strands 8, 9 and 10 and turns 8 and 9 which are the putative binding sites for heparin. For better 
visualization and a more accurate representation, only overlapping peptide segments in the flexible 
category (Figure 4A) are colored yellow in the crystal structure of FGF-1 (Figure 4 B) and only 
rigid peptides (Figure 4A) that do not overlap with flexible category peptides are colored blue. In 
addition, the flexibility of buried amide positions was also investigated and compared with the B 
–factors as determined by crystallography. The %HX value for buried amides (heat map color) 
was calculated as described in the methods section and was assigned to a secondary structure 






Figure 4.  Relative flexibility of FGF-1, as measured by HX-MS; (A) Flexibility, as measured form the ratio of 
the extent of deuteration at 13s relative to theoretical maximal exchange without correction for back exchange. 
Dark blue indicate rigid, yellow indicates flexible and grey indicates intermediate dynamics. Flexible (top) and 
rigid (bottom) regions are assigned (B) The flexibility categories are mapped onto the structure of FGF-1. All 





Figure 5. Secondary structure representation of FGF-1 with %HX values for buried amide positions. In the 
heat map, red indicates maximum HX while blue indicates minimum HX. 
 
The effects of polyanions on the local backbone flexibility of FGF-1:   Deuterium uptake changes 
for a peptide segment in the presence of a polyanion can be compared with unliganded FGF-1 to 
infer alterations in the local backbone flexibility of FGF-1 induced by ligation. In the presence of 
polyanions, there was either a decrease or no change in HX exchange at various time points. 
Representative deuterium uptake curves in Figure 6 show the effect of polyanions on the HX 
kinetics from different regions of FGF-1. For example, all four polyanions produced no change in 
hydrogen exchange in peptides 74-83 and 47-63. All of the polyanions induce a decrease in 
hydrogen exchange in the N –terminus region (peptide segment 8-15) and in peptide segments 98-





Figure 6.  Examples of the effects of different polyanions on the deuterium uptake in six representative segments 
from different regions of FGF. 
 
HX-MS analysis of FGF-1 with bound heparin: HX-MS analysis was performed at six labelling 
times ranging from 13s to 24 hr as shown in Figure 7B. Heparin at 0.2x by weight of FGF-1 was 
used since higher concentrations of heparin suppresses the ionization of FGF-1 peptides. Distinct 
changes in the rate of HX are seen in the presence of heparin. Shown in Figure 7A are two FGF-1 
peptides in which the peptide covering residues from 74-84 did not show any changes in the 
presence of heparin while peptides spanning residues 98-111 show a significant lowering in the 
exchange rate. Polyanions upon binding to FGF-1 decreases the rate of exchange in the areas of 
contact and thus represent potential binding sites of that ligand. Exchange rate differences between 
bound and unbound states were quantified as described previously (24). The magnitude of 






Figure 7A.  Deuterium exchange kinetics of two representative FGF-1 peptides. Panel A shows peptide 51 
(residues 74-84) where the rate of HX is not affected by heparin. Panel B shows peptide 81 (residues 98-111) 
where the rate of HX was slowed significantly by heparin. 
 
The ΔHX values for heparin are then time averaged to create ∆HX̅̅ ̅̅   plots as shown in Figure 8A. 
The results are analyzed in all cases based on these ∆HX̅̅ ̅̅  plots unless otherwise specified. Heparin 
protection of FGF-1 peptides is shown in a ∆HX̅̅ ̅̅   plot (Figure 8A) and the results are mapped onto 
the crystal structure of FGF-1 (Figure 9A). Heparin binding to FGF-1 caused a substantial slowing 
of HX in the N-terminus of FGF in four overlapping peptides (3, 4, 5 and 7) that span residues 8-
15. Strong protection is observed in four overlapping peptides (16, 17, 18 and 19) that span 
residues from 32-44. Heparin also caused strong protection in the C-terminus of FGF-1 in nine 
peptides (74, 76, 77, 80, 81, 83, 84, 85 and 86) that span residues 95-131. A heat map of buried 
amides of FGF-1 in the presence of heparin was calculated and mapped to the secondary structure 









Figure 7B.  HX-MS analysis of FGF-1 in the presence of heparin. Uptake at each HX time for FGF-1 labeled 
alone was subtracted from uptake when labelled in the presence of heparin, resulting in mass differences that 
are plotted at (C) 13 s,  (D) 100 s, (E) 1,000 s, (F) 10,000 s, (G) 30,000 s and (H) 86,000 s (24 hr) of labeling. 





Figure 8.  Relative protection of FGF-1 peptides by heparin, low MW heparin, phytic acid and ATP: HX-MS 
was performed with FGF-1 in the presence of (A) Heparin, (B) Low MW heparin, (C)Phytic acid and (D) ATP. 
The ∆𝐇𝐗̅̅ ̅̅  values for each FGF-1 peptide are shown and colored according to their k-means categorization: 




HX-MS analysis of FGF-1 with bound low MW heparin, phytic acid and ATP: Based on HX-MS 
analysis, low MW heparin produces strong protection in the same peptide segments seen with 
heparin (Figure 8B and 9B).  The magnitude of protection in the strongly protected peptides, 
however, is slightly less than heparin except in the case of peptide 19 (residues 42-44) where low 
MW heparin manifests slightly higher protection. Phytic acid also causes a substantial decrease in 
deuterium uptake in FGF-1 as seen in a ∆HX̅̅ ̅̅  plot (Figure 8C). Phytic acid addition again produces 
strong protection in peptides similar to heparin and low MW heparin. The magnitude of protection 
seen in the strongly protected regions is similar to heparin and low MW heparin, although the 
amount of phytic acid used is 2x by weight of FGF-1. Upon binding, ATP induced strong 
protection in the N –terminus of FGF-1 in five overlapping peptides (3, 4, 5, 6 and 7) that span 
residues 8-22. Strong protection is also seen in four overlapping peptides (12, 16, 17 and 18) that 
span residues 23-46. ATP also causes strong protection in the C-terminus of FGF-1 in four 
overlapping peptides (72, 74, 76, and 77) that span residues 90-111 as well as five overlapping 
peptides (80, 81, 83, 84 and 85) that span residues 98-117 (Figure 8D and 9D). The magnitude of 
protection observed in the strongly protected peptides was less than that seen with heparin, low 
MW heparin and phytic acid. It should be noted that ATP is significantly less polyanionic than the 
other three agents. Heat maps of buried amides of FGF-1 in the presence of low MW heparin, 
phytic acid and ATP were calculated and mapped to the secondary structure of FGF-1 









Figure 9.  Visual presentation of heparin, low MW heparin, phytic acid and ATP contact regions on FGF-1. 
The binding sites are mapped on to the structure of FGF-1 for (A) Heparin, (B) Low MW heparin, and (C) 






Figure 10.  Heat map for FGF-1 upon addition of heparin. Red color in the heat map indicates no change in 






At the peptide level, the HX determined flexibility of FGF-1 has shown that peptides that span 
strands 4 and 5 which form a hairpin-like structure along with turn 4 are rapidly exchanging with 
more than 60% of the theoretical exchangeable amides (Figure 4A). NMR studies have shown that 
the region which spans turn 4 has higher flexibility (17). Interleukin 1β which exhibits strong 
structural homology to FGF-1 has also been shown to have relatively higher flexibility in turn 4 
(17). Additionally, we have also seen peptides that span strand 7 and turn 7 possess greater 
flexibility. NMR studies find that the glycine at position 75 (proximal end of strand 7) exhibits the 
most rapid motion of all residues in FGF-1 (17). We see that C-terminal strand 12 has higher 
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flexibility. This can be explained since other β-strands are involved in strand pairing (forming a 
hairpin -like structure) while the C-terminal strand 12 is a separate strand (not involved in strand 
pairing) making it more flexible. The heparin bound form did not substantially alter the flexibility 
of FGF-1 in strand 12 (see figure 8A; peptides 87, 88 and 89) i.e. the plasticity still exists in strand 
12. This might be biologically relevant, since it includes residues Leu133 and Leu135 which define 
the regions of FGF-1 that are responsible for receptor binding. Other interaction sites that are 
critical for receptor binding include residues Tyr15, Ser17 (see figure 4A; peptides 8, 9 and 10); 
Arg35, Arg37 (see figure 4A; peptides 14 and 15); Glu87, Arg88, Leu89, Glu91, His93, Tyr94 
and Asn95 (see figure 4A; peptides 58-62). All are observed to be primarily in intermediate 
flexibility regions. The flexibility of those regions does not appear to be altered substantially by 
heparin binding (see figure 8A). Many molecular recognition processes involve induced fitting in 
which dynamic properties play an important role. Heparin binds and dimerizes FGF-1 and presents 
the growth factor to the receptor to form a ternary complex. The fact that the amino acid residues 
of FGF-1 that are involved in receptor binding remain flexible in the presence of heparin may 
reflect the ability of FGF-1 to have a broad–specificity for FGFRs. For the rigid regions, we 
observed peptides that span strands 2 and 3 which are involved in a strand pair are exchanging 
slowly as well as turns 2 and 3. In addition, we found peptides that span strand 6 and turn 6 are 
more rigid. This region appears to be a part of a core folding nucleus. Strands 8, 9 and 10 in the 
C-terminus region are also seen to be rigid. This is confirmed by NMR in which it is observed that 
the strands in the C-terminal region are more rigid than other strands that form the β-barrel (17).  
          Upon analyzing HX-MS data at the residue level, residues with the lowest %HX values 
include a number of hydrophobic amino acids that contribute to the cooperative central 
hydrophobic core packing group, including Ile25, Phe85, Val109, Leu111 and Phe132 (11). The 
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14 residue region of positions 98-111 includes eight positions identified as being among the lowest 
%HX values (Figure 5). This region comprises an extended structural loop in the third trefoil fold 
domain. Several of these positions have no direct structural equivalent in terms of the C3 structural 
symmetry. In the crystal structure of FGF-1 bound to the FGFR-1 ectodomain (1EVT), this region 
of FGF-1 makes no contact with the receptor(29). In the crystal structure of FGF-1 with FGFR2 
and heparin (PDB accession 1E0O) (3), this region makes contact with the heparin fragment 
(Lys105, Trp107).  In the crystal structure of FGF-1, FGFR1c and HS (PDB accession 3OJV) this 
loop makes no contact with the receptor or HS (7). In the crystal structure of the FGF-1, FGFR2D2 
and sucrose octasulphate (SOS) complex (PDB accession 3CU1), this portion of the molecule 
makes no contact with either receptor or SOS. Leu44 is related to Phe85 and Phe132 by the pseudo-
threefold symmetry of the FGF-1 β-trefoil architecture. Unlike Phe85 and Phe132, however, Leu44 
exhibits a distinctly larger %HX value. The crystal structure of FGF-1 identifies a cavity adjacent 
to Leu44 - large enough to accommodate the aromatic ring of a Phe mutation with no structural 
distortion (11). Thus, the increased %HX at position Leu44 is most consistent with a core-packing 
defect (e.g. a cavity) that permits structural flexibility. The HX data for FGF-1 exhibits as expected 
a general trend of low HX for residues located in β-strands, and higher HX for residues in turn 
regions. 
         From the crystal structures, the lowest average C B-factors are found in a generally 
contiguous region spanning residue positions 56-132 (i.e. approximately the C-terminal two-thirds 
of the protein). The majority of C positions exhibiting the lowest average B-factors in this C-
terminal region are hydrophobic amino acids that contribute to the core packing group of the 
protein (including Ile56, Met67, Cys83, Phe85, Tyr97, Phe108, Val109 and Phe132). Residue 
positions exhibiting the lowest HX values include Phe85, Val109, Ile111, Phe132 and Leu133. 
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Residue positions in this group also identified as buried hydrophobic amino acids exhibit the 
lowest B-factor values in the X-ray structure. Residue positions 44 - 55 (i.e. β-strands 4 and 5) are 
distinctive in exhibiting the highest HX values in the protein overall. The core-packing defects in 
the region of position 44 (i.e. at the interface of the first trefoil fold with the rest of the protein) 
thus not only increase the general atomic motion, but also the apparent solvent penetration of the 
N-terminal region described by β-strands 1-5. In this regard, β-strands 4-5 appear extremely 
sensitive to solvent penetration. The HX data are therefore consistent with the X-ray structure data 
- including isotropic B-factors and packing defects (i.e. cavities) within the core of the structure. 
The HX data identify increased solvent penetration for the β-4/β-5 strand region in comparison to 
B-factors for this region, which appear consistent with the presence of internal cavities. 
         A remarkable fact seen with all four polyanions is that the relative intensities of the ∆HX̅̅ ̅̅  
values among the individual peptides is in most cases highly similar. This suggests a high degree 
of specificity in the location of the polyanion binding sites using this method. FGF-1 is known to 
have high affinity for large negatively charged molecules like heparin, membrane bound HSPG as 
well as smaller polyanions (30, 31). Studies show that various polyanions in FGF-1 solutions 
dramatically increase its stability and potency (32). HSPGs also play a key role in the distribution 
of FGF-1 at the tissue level. Thus, polyanion binding appears to be playing a crucial role in the 
biological function as well as in the stability of FGF-1. A large number of crystallographic as well 
as NMR studies have revealed the amino acid positions associated with heparin binding in FGF-
1. A specific cluster of basic amino acids with significant positive charge density in the N-terminus 
(first β-hairpin) and C-terminus (last two-thirds of the third trefoil domain) are seen to be 
responsible for heparin binding. The above structural data has been complimented by a variety of 
function studies involving chemical modification, point mutations, deletions, homologous 
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substitution mutations, and peptide-binding competition studies in combination with analytical 
ultracentrifugation, surface plasmon resonance and affinity chromatography (14, 33-36). In 
addition to sulfated heparin and similar molecules, it has also been found that phosphate and 
carboxyl containing compounds stabilize FGF-1 against thermal unfolding. The common feature 
in such compounds is the presence of one or more large negatively charged regions. As the number 
of sulfates, carboxylates and phosphates increase, the ability of such polyanions to stabilize FGF-
1 also generally increases. In addition to electrostatic interactions, the trigonal pyramidal geometry 
of sulfates and phosphates makes it possible to form  hydrogen bonds between charged groups 
(37). Here we tested four polyanions, two sulfate containing polymers including heparin and low 
MW heparin and two phosphate containing compounds, Phytic acid and ATP. 
         Using HX-MS, we were able to see strong protection in the C-terminal domain region as well 
as in the N-terminus regions which are rich in positively charged amino acids. At a residue level, 
heparin binding provides increased protection for amides within the first trefoil fold - especially 
positions 12, 13, 15, 44 and 45. Conversely, heparin binding does not alter the HX protection of 
residues within the second trefoil fold. In the third trefoil fold, heparin binding increases HX 
protection for residue positions 109-123, with the greatest decrease in HX rates observed for 
position 112 and 115. In the crystal structure of the ternary complex of FGF-1/FGFR2/heparin 
(PDB accession 1E0O) bound heparin interacts (via salt bridges, H-bonds or van der Waals 
interactions) with Asn18, Lys105, Tryp107, Lys112, Lys113, Arg119, Pro121, Arg122, Gln127, 
Lys128 (38). Thus, the increased HX protection upon heparin binding observed for residue 
positions 12, 13 and 15 in the first trefoil fold domain appear due to the interaction between heparin 
and adjacent Asn18. In this regard, local structural effects due to heparin binding seem to be 
communicated to adjacent position Leu44 (which also increases protection of Gln45). The 
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increased HX protection of residue positions 109-123 in the C-terminus trefoil fold domain is 
consistent with extensive heparin interactions with residues in this region. In this regard, this part 
of FGF-1 is rich in basic amino acids which provide a charge partner to heparin sulfonate groups. 
In this region, Lys112 exhibits one of the major increases in HX protection, potentially identifying 
Lys112 as one of the more significant salt bridge interactions between FGF-1 and heparin. 
         Similar regions of increased HX protection are observed for all polyanions. This involves 
primarily N-terminal residue positions 12, 13, 15, 44 and 45, and C-terminal positions 109, 111, 
112, 115, 120, 122, and 123 (See supplementary Figure 3, 4 and 5). The magnitude of ∆HX̅̅ ̅̅  
protection is, however, a function of the size/charge (charge density) of the polyanion. Thus, ATP 
exhibits the weakest overall ∆HX̅̅ ̅̅  protective effect, while heparin exhibits the greatest (Fig 8). Low 
MW heparin exerts essentially identical ∆HX̅̅ ̅̅  values as seen with heparin; the main distinction is 
a slight reduction of HX protection at residue positions 12, 13, 15, 112 and 115. Interestingly, the 
amount of heparin used was the lowest in terms of molar ratio with FGF-1 while ATP was the 
highest, yet the protection with heparin is more than ATP indicating the importance of a polyanion 
carrying more negative charges for strong affinity. It was also reported that heparin favors 2:1 and 
3:1 FGF/heparin sulfate complexes as the protein concentration increased (39).  Binding of the 
comparatively small ATP polyanion exerts ∆HX̅̅ ̅̅  effects that involve a characteristic distribution 
of N and C-terminus positions also associated with larger polyanion binding. This suggests a 
generalized induced-fit structural response associated with anion binding, which involves specific 
positions in the N- and C-termini trefoil-fold motifs. As discussed above, binding of anions at 
position Asn18 appears to communicate HX changes to adjacent positions 12, 13, 15, 44 and 45. 
Position 45 is associated with core-packing defects that may permit induced fit changes. 
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         In all cases of polyanion binding the central trefoil fold appears devoid of any large ∆HX̅̅ ̅̅  
effects; thus, the central trefoil fold region is not directly associated with anion-binding. This 
central region has been identified as a major part of the FGF-1 folding nucleus (15). A 
"folding/function" tradeoff has been proposed for the general organization of the FGF-1 primary 
structure (potentially a general theme in protein evolution) (15, 40), and the HX data supports this 
hypothesis, in which heparin strongly interacted with the functional C-terminus while no 
substantial interaction is seen in the core folding region of FGF-1 .                                                                 
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Supplementary Figure 2. C isotropic B-factors of FGF-1. Values are the average from six independent 
molecules crystallized in two different space groups. Residue positions 10-137 are consistently structured in all 
crystal forms (thus, residue positions 1-9 and 138-140 can be considered as having the equivalent of a red color 








Supplementary Figure 3. ΔHX heat map for FGF-1 upon addition of low MW HS. Red color in the heat map 
indicates no change in HX values upon binding of low MW HS to FGF-1; blue color indicates an increase in 












Supplementary Figure 4. ΔHX heat map for FGF-1 upon addition of phytic acid. Red color in the heat map 
indicates no change in HX values upon binding of HS to FGF-1; blue color indicates an increase in HX 









Supplementary Figure 5. ΔHX heat map for FGF-1 upon addition of ATP. Red color in the heat map indicates 
no change in HX values upon binding of ATP to FGF-1; blue color indicates an increase in HX protection. The 













Supplimentary Table 1.  FGF-1 peptic peptides 
 
Pep # start end  Pep # start end  Pep # start end     
1 1 7  36 54 63  71 90 96     
2 1 9  37 54 64  72 90 97     
3 8 13  38 54 65  73 95 108     
4 8 14  39 54 67  74 95 111     
5 8 15  40 55 64  75 97 107     
6 8 22  41 55 67  76 97 110     
7 9 13  42 56 64  77 97 111     
8 14 22  43 56 67  78 98 107     
9 15 22  44 65 67  79 98 108     
10 16 22  45 65 73  80 98 110     
11 23 34  46 66 73  81 98 111     
12 23 36  47 68 73  82 99 104     
13 23 43  48 74 81  83 107 110     
14 28 40  49 74 82  84 108 110     
15 29 40  50 74 83  85 109 117     
16 32 36  51 74 84  86 118 131     
17 41 44  52 74 85  87 122 136     
18 41 46  53 82 84  88 132 140     
19 42 44  54 82 85  89 133 140     
20 45 49  55 83 85  90 134 140     
21 45 50  56 83 86         
22 45 53  57 84 89         
23 45 55  58 85 89         
24 47 53  59 85 91         
25 47 54  60 85 94         
26 47 55  61 85 96         
27 47 63  62 85 97         
28 49 53  63 85 108         
29 49 55  64 85 110         
30 49 64  65 85 111         
31 50 55  66 86 89         
32 50 63  67 86 94         
33 50 64  68 86 96         
34 50   67  69 86 97         































Ricin is a fast acting protein toxin that is classified as a potential agent of bioterrorism (1, 2).   
Currently, two leading subunit vaccine candidates centered on ricin toxin chain A (RTA) namely 
RiVax and RVEc are under development for ricin toxin. RiVax is a full length derivative of RTA 
with two point mutations, while, RVEc is a truncated version of RTA which is relatively more 
stable than RiVax. Phase 1 clinical trials have been performed for both vaccine candidates (3, 4). 
Both RiVax and RVEc are deemed to be safe in humans, however, neither of them were 
particularly effective in eliciting toxin neutralizing activity (TNA), which is a key measure of 
vaccine efficacy. Hence, there is a need to develop more potent vaccine candidates for ricin. To 
date, the rationale for designing subunit vaccine candidates for ricin has been focused on 
developing safer and stable derivatives of RTA. The results of RiVax and RVEc phase 1 clinical 
trials made it clear that in order to redesign a potent vaccine candidate based on RTA, an 
immunological rationale has to be elucidated and implemented. Immunity against ricin is antibody 
mediated. Understanding immune responses to RTA and ricin toxoid has been challenging as 
immunization elicited a complex mixture of antibodies (Abs) including toxin neutralizing, non-
neutralizing and toxin-enhancing Abs (5, 6). It was also reported that neutralizing antibodies 
constitute only a minor portion of the total antibodies elicited against RTA (7). Therefore, having 
a comprehensive B-cell epitope map on the surface of ricin would aid in the development and 
evaluation of effective ricin vaccines. In fact, efforts to develop an effective ricin subunit vaccine 
are obstructed by lack of B cell epitope information on ricin’s enzymatic (RTA) and binding (RTB) 
subunits which are important in eliciting protective immunity.  
To this end, a great deal of work has been done to performed structural epitopes on RTA. O’Hara’s 
et al. work has found that serum antibodies of RiVax-immunized mice and rabbits reacted with six 
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immune dominant liner regions on RTA(7). The work in that report was limited to linear epitopes, 
in which the majority of antibodies elicited (>85%) target conformation dependent epitopes. 
Hence, it is important to map conformational dependent epitopes on RTA. In a later report, 
conformational epitopes were located on RTA using competitive binding assays (8). It was also 
reported that toxin neutralizing antibodies are limited to four spatially distinct regions on the 
surface of RTA, which we refer to as epitope clusters I-IV.  
 This dissertation sought to construct a B cell epitope map on the surface of ricin toxin chain A, 
RTA.  For safety reasons, we have worked on a safer version of RTA, namely RiVax. Structurally 
both RiVax and RTA are virtually identical to each other. Therefore, we used RiVax in this 
dissertation to identify structural epitopes. To facilitate this, we have purified this recombinant 
version of RTA (RiVax) using E.coli as an expression vector. Once RiVax was purified, we have 
characterized the protein for its structural integrity and conformational stability (see appendix) as 
our interest lies in identifying conformational epitopes. In all, we have purified six batches of 
RiVax, of which, lot 3 was used for epitope mapping studies. RiVax was extensively characterized 
using various bio-physical techniques including intrinsic tryptophan fluorescence, circular 
dichroism, differential scanning calorimetry, static light scattering and size exclusion 
chromatography. Bio-physical analysis confirmed that RiVax structure is in a conformationally 
folded state which is essential for identifying conformational/ discontinuous epitopes. The melting 
temperature (Tm) values obtained using various analytical techniques were in good agreement 
with that of previous RiVax characterization work conducted in our lab (9). RiVax was also tested 
for the presence of disulfide bond induced aggregates using SDS-PAGE.  Intact mass revealed that 
there are no significant modifications associated with RiVax.  
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In chapter 2, RiVax was subjected to epitope mapping using hydrogen exchange mass 
spectrometry (HX-MS). Of the four epitope clusters (I-IV) that were identified on the surface of 
RTA, cluster III is recognized by only one mAb, namely IB2. Cluster III attains importance in that 
the toxin’s active site is surrounded by it. In an effort to gain a greater understanding of this region, 
we used a large collection of single domain antibodies (VHHs) that are directed towards cluster III. 
We previously reported the binding site of cluster III defining mAb, IB2 using HX-MS (10). IB2 
engaged with secondary structural elements including helices C and G on the surface of RiVax. In 
this chapter, we described twenty one VHHs directed against an immunodominant region, 
designated as epitope cluster III (Siva Angalakurthi et.al. manuscript in preparation). HX-MS 
analysis revealed that all twenty one antibodies that were studied have overlapping epitopes i.e. 
they share at least one common secondary structural element in their epitope. Based on their 
contact with secondary structural elements on the surface of RiVax, we found there are four 
subclusters (3.1-3.4) within cluster III region. Subcluster 3.1 includes helices C and G. Subcluster 
3.2 encompasses helices B, C and G. subcluster 3.3 consists of helices B and G. Lastly, subcluster 
3.4 includes strand h and helices C and E.  Of the 21 antibodies, only two, namely V1D3 and V6D4 
have shown TNA. V1D3 and V6D4 have shown strong affinity (sub nanomolar range) for the 
toxin. V1D3 fell into subcluster 3.1 i.e. it engaged helices C and G. While, V6D4 was categorized 
into subcluster 3.3 i.e. its epitope included helices B and G. Both neutralizing antibodies shared a 
common secondary structural element in the form of helix G in their epitopes. V1D3 which falls 
into subcluster 3.1 include a collection of 16 antibodies, whose HX-MS protection profiles look 
similar to V1D3. Interestingly, none of the antibodies except V1D3 has shown TNA. It should be 
mentioned V1D3 is one of the strong binders we found in this cluster. We speculate that V1D3’s 
strong binding affinity (< 200pM) to the toxin could be one of the reasons for its TNA. Another 
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neutralizer, V6D4 falls into subcluster 3.4 which engages with helices B and G. Also, we observed 
V1D3 and V6D4 (the only neutralizing antibodies in this study) epitopes have helix G in common. 
We believe that binding affinity and epitope specificity (in this case, helix G) plays critical role in 
neutralizing activity.  It is clear that further studies will be necessary to clarify the origins of 
neutralizing activity.   
In chapter 3, we studied protein-small molecule interactions i.e. we sought to identify the binding 
sites of polyanions on the surface of FGF-1. FGF-1, which is unstable at room temperature is 
known to exhibit high conformational stability in the presence of heparin (polysulfate anion). 
Volkin and Middaugh’s work have shown that FGF-1 exhibited increased thermal stability not 
only in the presence of heparin but also in the presence of a number of other sulfated and 
phosphorylated molecules (11). Based on those studies, we have selected and studied two sulfated 
molecules including heparin and low MW heparin and two phosphorylated molecules, namely 
phytic acid and adenosine triphosphate (ATP). All molecules have been shown to enhance the 
thermal stability of FGF-1 and the trend followed as: Heparin > low MW heparin > Phytic acid > 
ATP. We have used HX-MS to identify the binding sites of these polyanions on the surface of 
FGF-1. Based on HX-MS results, all four polyanions were shown to have similar protection 
profiles i.e. they bind to similar regions on FGF-1. Analysis revealed that the dense negatively 
charged polyanions interacted primarily with a positively charged patch in the C-terminus as well 








As a part of long standing efforts to generate a complete antigenic map of ricin toxin and to better 
define the epitopes associated with neutralizing activity, we have extensively studied cluster III 
using a collection of single domain antibodies. Although it is difficult to predict what makes an 
antibody neutralizing based on our studies in chapter 2, we speculate that helix G contact on RTA 
plays a crucial role in neutralizing activity. The fact that a number of antibodies (in subcluster 3.1) 
having similar epitopes to V1D3 (neutralizing antibody), yet none of them show any toxin 
neutralizing activity indicates that a deeper understanding of these antigen-antibody interactions 
at the single residue level is required. Some of the non–neutralizing antibodies have shown 
stronger binding affinity values than neutralizing antibodies. This further substantiate the need to 
identify those critical residue contacts. In addition, the manner by which these antibodies bind to 
the toxin i.e. the angle of contact, could also provide some insight into toxin neutralizing activity. 
To this end, studies have been initiated to solve crystal structures of toxin-antibody complexes. It 
is not the first time we see antibodies having similar/ overlapping epitopes yet showing different 
toxin neutralizing activity. Our collaborators have already showed how a single residue contact 
can effect the binding affinity and toxin neutralizing activity (12). Once the co-crystals are solved, 
it would be interesting to verify/ validate to what extent helix G plays a crucial role in neutralizing 
activity by engineering the CDR region of antibodies that interacts with helix G as well as by 
performing point mutations in helix G. It would also be interesting to see how these antibodies 




As a part of generating a complete antigenic map of ricin toxin, extensive epitope mapping studies 
have been conducted on the RTA subunit. As a reminder, four epitope clusters have been identified 
on RTA. Cluster I and II have been studied previously. In this study, we reported results for cluster 
III. The cluster IV region is located in the more disordered C –terminus region of RTA.  Although, 
studies in mice have shown that this cluster elicits mainly non-neutralizers, it is worth pursuing 
studies to gain a better understanding of the cluster IV region using VHHs. The fact that VHHs are 
often able to see cryptic regions could help in defining neutralizing and non-neutralizing epitopes 
in cluster IV since it is this region that binds to the RTB subunit by a disulfide bond. This region 
is crucial due to the fact that ricin in the endoplasmic reticulum (ER) undergoes disulfide reduction 
to get A chain free from its B chain counterpart which allows RTA to enter into the cytosol and 
eventually target ribosomes.  
Thus far, much attention has been directed to the RTA subunit since it contains the active site. In 
the future, we will start mapping epitopes on the RTB subunit. It would be interesting to see if 
there are any toxin neutralizing antibodies that are directed towards this subunit. In this case, 
solving crystal structures of toxin neutralizing antibody- RTB complexes would not only help in 
identifying the CDR region that is interacting with RTB but also in rationale engineering of CDR 
regions for developing therapeutics against ricin. Since RTB helps the toxin entry into the host 
cell, developing therapeutics that target RTB subunit might block ricin from entering into cell.   
Once a complete antigenic map is constructed on both subunits using a collection of murine mAbs 
and VHHs, the next step would be validating B cell epitopes identified on RTA in humans. As said 
previously, two leading subunit vaccine candidates based on RTA (RiVax and RVEc) have 
undergone phase 1 clinical trials. Identifying B cell epitopes on RTA recognized by human 
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vaccines by evaluating clinical sera would have important ramifications for the advanced 
development of an RTA based subunit vaccine. 
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Appendix A. Purification and biophysical characterization of RiVax 
For an epitope mapping study, an antigen and its cognate antibody is required. In this case, the 
protein antigen was a recombinant ricin toxin chain A, RiVax. The monoclonal antibodies that are 
specific to ricin are produced in mice by hybridoma cell technology in which mice are immunized 
by ricin toxoid/ RTA/RTB or a mixture of subunits. Along with murine monoclonal antibodies, 
we have also worked with single domain antibodies. These are produced by immunizing alpacas 
with ricin toxoid and non-toxic mixtures of RTA and RTB. One of the main goals in this 
dissertation is identifying discontinuous (conformational) epitopes on the surface of RiVax. Hence, 
it is necessary to characterize the structure of RiVax for its structural integrity as discontinuous 
epitopes cannot be identified if the protein antigen structure is unfolded. We have purified 6 
batches of RiVax, of which, lot 3 was used to conduct epitope mapping studies. RiVax was 
characterized in the same buffer conditions (25mM sodium phosphate, 150 mM NaCl, pH 7.4) as 
those used in epitope mapping studies.    
Materials and methods:  
Sample preparation: 25 mM phosphate buffer containing 150mM NaCl at pH 7.4 was prepared 
using an appropriate amounts of monobasic and dibasic sodium phosphate (Fisher). RiVax stock 
was stored in histidine buffer with 10%w/v sucrose at -80oC. Prior to experiments, RiVax was 
thawed and then dialyzed into 25mM phosphate buffer (pH: 7.4) at 4oC using Slide-A-Lyzer 
Dialysis cassettes of 10 kDa MWCO (Pierce, Rockford, IL). The concentration of RiVax was 
determined by UV spectroscopy employing an extinction coefficient of 0.83 mL/mg.cm.   
Intrinsic tryptophan fluorescence: Intrinsic fluorescence spectra was measured using a Photon 
Technology International (PTI) spectrofluorometer equipped with a turreted 4-position peltier 
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temperature controller. RiVax has a single tryptophan and an excitation wavelength of 295 nm 
(>95% Trp emission) was used.  Emission spectra were collected from 305-405 nm by a 
photomultiplier with a slit width of 3nm and an integration time of 1s. Fluorescence spectra were 
collected at 2.5oC intervals with an equilibration time of 3 min at each temperature from 10-87.5oC. 
A 1- cm path length quartz cuvette was used for all experiments. Data analysis was performed 
using FelixTM (Photon Technology International) software. Prior to data analysis, a buffer spectrum 
was subtracted from each protein sample spectrum. Using a mean spectral center of mass method 
(msm) executed in Middaugh Suite, the emission wavelength maximum was determined. This 
method although increases the signal to noise ratio for more accurate determination of λ max values, 
it shifts the apparent peak by 5-10 nm from their actual value.  Tm values were determined using 
a first derivative method on origin 7.0 software.   
The PTI fluorometer has a second detector that is located at 180o to the fluorescence detector which 
is used to study the aggregation behavior of RiVax. Light scattering data was obtained 
simultaneously during the florescence experiments. The scattering intensities were collected at 295 
nm (the fluorometer excitation wavelength) with slit width of 0.5-nm slit width as a function of 
temperature ranging from 10oC- 87.5oC.    
Circular Dichroism: Far-UV CD spectroscopy was conducted using a Chirascan-plus circular 
dichroism spectrometer (Applied Photophysics Ltd) furnished with a peltier temperature controller 
and a 4 position cuvette holder. The CD spectra were collected from 195 – 260 nm using a 0.1 cm 
path length cuvette. Thermal melt experiments were performed from 10-90oC at 2.5oC interval and 
a heating rate of 10oC/min. The CD signal at 208nm was monitored to follow the changes in 
secondary structure as a function of temperature. Prior to data analysis, buffer subtraction was 
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performed and an average of triplicate sample measurements were employed. Thermal melting 
temperature (Tm) values were obtained by a first derivative method using Origin software.    
Differential scanning calorimetry: Differential scanning calorimetry (DSC) was performed using 
a Microcal VP-DSC capillary cell microcalorimeter (Microcal, Northampton, MA). Thermograms 
were collected over a temperature range of 10-90C with a scan rate of 1oC /min. A concentration 
of 1.5 mg/ml of RiVax was used and measurements were made in triplicate. Prior to analysis, a 
buffer thermogram was subtracted from each protein measurement and the data were normalized 
to molar heat capacity. Data were processed using Microcal DSC software in origin 7.0 (Origin 
Lab, Northampton, MA). The data were fit using a mathematical model in origin 7.0. The onset 
temperature (T onset) was taken as the temperature at which the heat capacity exceeded 500 cal   
mol-1 oC-1. 
SDS-Gel studies: SDS-PAGE was conducted on RiVax samples under both reducing and non-
reducing conditions. Samples were prepared by mixing protein with 4X NuPAGE-LDS sample 
buffer (Life technologies, Grand Island, NY) to a final concentration of 1X. For reduced samples, 
50Mm dithiothreitol (DTT) was added. Samples were then heated for 5 min at 95oC. Twenty µg 
of RiVax protein was analyzed by SDS-PAGE using 1X MES running buffer and a 4-12% Bis-
Tris gradient gel. Gels were stained using coomassie blue R250 to visualize protein bands and 
ultrapure water was used for destaining.   
Size exclusion chromatography (SEC): A Shimadzu Prominence UFLC HPLC system equipped 
with a photodiode array detector was used. To remove insoluble aggregates, RiVax samples were 
centrifuged at 13000rpm for 5 min. SEC was performed by injecting 20 µg of RiVax onto a 7.8 
cm X 30 cm TSK-GEL BioAssist G3SWXL column (TOSOH Biosciences, King of Prussia, PA). 
The mobile phase was 20 mM sodium phosphate buffer (pH 7.4) and a flow rate of 0.7 ml/min 
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was maintained with a 30 min run time. To ensure the column and HPLC system integrity, a gel 
filtration standard (Bio-Rad, Hercules, CA) was run before and after the RiVax runs.  Data analysis 
was conducted using LC-solution software (Shimadzu). The chromatograms were analyzed by 
integrating the peak area of monomer, dimer/trimer and higher order aggregates at 280nm.The 
relative area of the monomeric peak to the total peak area was used to calculate the monomer 
percentage in the sample. 
Protein purification:  The gene encoding RiVax with an N-terminal his tag which can be cleaved 
by tobacco etch virus (TEV) protease was subcloned into a ligation independent vector. Plasmid 
DNA was transformed into chemically competent BL21-RARE E.coli cells via heat shock 
(~42oC). Using an LB/agar plate, positive colonies containing gene of interest were identified.       
Cells were grown in a 4L flask (containing 2L of culture media) at 37oC with shaking at ~250rpm 
until an optical density of 0.5 was obtained. Cells were then induced by isopropyl β-D-1-
thiogalactopyranoside (IPTG). A concentration of 0.2 mM IPTG was used. Before inducing with 
IPTG, the cells were pre-cooled to 15oC. Cells were expressed overnight (~16hr) at 15oC with 
shaking at ~250 rpm. Cells were harvested in a centrifuge (Beckman coulter 25R) at 4oC for 10 
min at 4000rpm. After centrifugation, the supernatant media was drained and cell pellets were 
recovered and resuspended thoroughly with 50mM Tris (pH 8). Cells were then stored at -80oC 
for a few days and later thawed at room temperature in a water bath. Using a sonicator (Fisher 
scientific sonic dismembranator model 500), cells were lysed. During sonication, the cells were 
kept at 4oC by placing in an ice bath to minimize protein denaturation. The lysed cells were then 
centrifuged and the supernatant was collected and filtered through 0.2 µm filter. The supernatant, 
which contains the protein of interest, RiVax, is then injected using an AKTA prime system onto 
a His Trap (5ml) Ni+2 affinity column (GE health care, Piscataway, NJ). The His tag protein which 
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binds to the Ni+2 column is eluted using a 50mM imidazole solution. The purified 6X his-tag RiVax 
was then subjected to TEV protease for his-tag cleavage. TEV protease and RiVax were mixed at 
a ratio of 1:20 respectively and dialyzed (cleaved his-tag dialyzed out) overnight in 50mM Tris 
buffer (pH 8). The protein solution, which contains RiVax and his tag TEV protease, was later 
purified using a Ni+2 column by gravity flow. RiVax was collected into a 96 well plate. Using a 
Nanodrop spectrometer the wells corresponding to RiVax were identified and pooled. RiVax was 
then dialyzed into 10mM histidine buffer, 150mM NaCl containing 10% w/v sucrose. Protein 
samples were then diluted to 1mg/ml and aliquots of 1ml were stored at -80oC for long term 
storage.    
Intact mass: RiVax’s intact mass was analyzed on a model 6530 quadrupole time of flight (QTOF) 
mass spectrometer. Protein sample was injected into a liquid chromatography (LC) system, bound 
to a C8 column trap, desalted and then subjected to electron spray ionization and finally into the 
TOF analyzer for mass determination. RiVax’s intact mass was determined by deconvoluting the 












Result and Discussion: 
 
 
Figure 1: Left panel indicates the circular dichroism spectra of RiVax at 10oC. Right panel indicates the thermal 
melting curve of RiVax obtained by following the molar elliptically at 208 nm as a function of temperature.   
 
The secondary structure content of RiVax was characterized by Far-UV CD. A concentration of 
0.2mg/ml of RiVax was used for the experiment. The left panel (Figure 1) represents the CD 
spectrum collected at 10oC. At 10oC, two minima were observed at 208 and 222 nm suggesting 
that the secondary structure content of RiVax is primarily of α-helical. This is consistent with the 
crystal structure of RiVax (PDB: 3SRP) where it is reported that nearly 40% of the protein is α-
helices. Since the minimum at 208 nm is intense than the one at 222nm, we monitored the 208nm 
minimum to evaluate the loss of secondary structure. As observed from Figure 1 (right panel), 
RiVax tends to lose its secondary structure since the molar ellipticity increased as a function of 
temperature. Upon analyzing the CD thermal melt curves of RiVax, a Tm value of ~47.5
oC was 














































































determined. The Tm value determined here (sodium phosphate buffer, pH 7.4) is similar to Peek 
and co-workers results (Tm ~ 44-52, citrate phosphate buffer, pH 7.0) that was previously published 
from our lab (1).   
 
Figure 2: Fluorescence emission spectra of RiVax at 10oC (left panel). Thermal melt curve of RiVax obtained 
by following changes in the wavelength emission maximum as a function of temperature (right panel).    
 
 
RiVax (267 amino acid residues) has one tryptophan at position 211 in its primary sequence. 
Tryptophan is sensitive to the polarity of its environment. The excitation wavelength of 295 nm 
produces almost exclusively Trp emission. The fluorescence spectrum of RiVax at 10oC showed 
an emission maxima (λmax) at 330 nm (Figure 2, left panel), indicating that the lone tryptophan 
residue is located in a relatively hydrophobic environment. The effect of temperature on the MSM 
fluorescence peak position of RiVax was shown in Figure 2 (right panel). With increased 
temperature, λmax red shifted indicating the Trp residue to be in a relatively more polar 
environment, implying structural alterations in RiVax’s tertiary structure upon heating. Upon 
analyzing the fluorescence thermal melt curve, a thermal transition Tm value of ~ 46
oC was found. 


















































RiVax’s aggregation behavior was studied by monitoring the light scattering at 295 nm (i.e. the 
excitation wavelength used for fluorescence) simultaneously during intrinsic fluorescence 
spectroscopy. Light scattering from RiVax was monitored as a function of temperature ranging 
from 10-87.5oC. Light scattering started to increase around 35oC presumably due to aggregation 
of RiVax.              The scattering intensity started to drop after 45oC, a result due to precipitation 
of the protein (Figure 3). 
 
 
Figure 3: Aggregation propensity analysis of RiVax as analyzed by static light scattering as a function of 
temperature.    
 
RiVax purity and size were assessed by SDS-PAGE. RiVax is unfolded by the SDS and was run 
under both reduced and non-reduced conditions. RiVax manifests the expected single band under 
reducing conditions where the apparent MW of the band (~ 28kDa) corresponds to that of  RiVax 





























(theoretical MW: 29.9 kDa). Under non-reducing conditions, two protein bands were observed (~ 
28kDa and ~ 51kDa) corresponding to RiVax’s monomer and dimer respectively. RiVax has a 
cysteine on the surface and the small amount of dimer formation in the non-reduced condition is 
attributed to intermolecular disulfide bond formation. This was supported by the disappearance of 

































Figure 5: Representative DSC thermogram of RiVax. Conformational stability of RiVax was monitored as a 
function of temperature by DSC.    
 
The overall conformational stability of the RiVax was followed by DSC. A concentration of 1.5 
mg/ml of RiVax was used for the experiment. As shown in Figure 5, one major endothermic peak 
was observed at approximately 46oC with an onset temperature (T onset) at nearly 40
oC. It should 
be mentioned that the conformational stability of RiVax (20mM citrate phosphate, pH 7.0) was 
determined by DSC previously from our lab where RiVax has shown a broad endothermic peak at 
approximately 43oC and is subsequently fitted to 2 transitions (Tm1 ~ 42
oC and Tm2 ~48
oC) with 




Samples T onset Tm 
RiVax Lot 3 39.8 ± 1.1 °C 46.3 ± 0.3 °C 






















Figure 6: Size analysis of RiVax. The size and distribution of monomer and aggregate species in RiVax as 
evaluated by SEC. The molecular weight (MW) values of gel filtration standard proteins are shown in the SE 
chromatogram.      
 
RiVax was also analyzed for the presence of monomer and aggregate species by SEC. Analysis of 
the SEC chromatogram (Figure 6) showed that RiVax eluted primarily as a monomer (~94%). A 
small amounts of dimer/timer and higher aggregate species were also observed. It is essential to 
characterize RiVax samples for the presence of aggregate species since having significant 
















































































Figure 7: Primary structure analysis of RiVax. Intact mass spectrum of nonreduced RiVax. Theoretical intact 
mass of RiVax is 29920.66 (nonreduced). 
 
Intact mass was analyzed to elucidate the molecular composition of RiVax. As shown in Figure 7, 
a single species was observed in the deconvoluted spectrum of RiVax. The observed mass of 
RiVax matches with that of theoretical mass (29920.66 Da) implying that the species is an 











































































































































































In conclusion, RiVax was characterized for its structural integrity and conformational stability. 
RiVax’s conformational stability was evaluated as a function of temperature and found to be 
consistent with that of previous work performed by Peek et.al (1). RiVax was shown to exist in a 
folded state as revealed by various biophysical techniques including spectroscopy, DSC and light 
scattering which is critical for identifying discontinuous/ conformational epitopes on the surface 
of RiVax. The other aspects including aggregation and chemical modifications of RiVax were also 
tested. It is essential to ensure that RiVax is not in its aggregated form since the aggregation 
hotspot/ interface could obstruct/slower deuterium uptake and could lead to misinterpretation of 
HX-MS analysis. Using Size exclusion and SDS-PAGE we did not observe any significant 
aggregates in RiVax. Intact mass results ensured that there aren’t any significant post translational 
modifications on the surface of RiVax. It is possible that any significant post translational 
modification on RiVax could hamper antibody binding, if the antibody targets a region close to 
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